Page last updated: 2024-11-06

esmolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Esmolol is a short-acting beta blocker that is used to treat high blood pressure and other cardiovascular conditions. It is a synthetic compound that is administered intravenously. Esmolol works by blocking the effects of adrenaline and noradrenaline on the heart, which helps to slow the heart rate and lower blood pressure. Esmolol is particularly useful in treating acute hypertensive emergencies and in managing hypertension during surgery. The short duration of action of esmolol makes it a safe and effective option for treating acute conditions. Research on esmolol continues to focus on its potential uses in other cardiovascular conditions, as well as its safety and efficacy in different patient populations.'

methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID59768
CHEMBL ID768
CHEBI ID88206
CHEBI ID4856
SCHEMBL ID3605
MeSH IDM0111364

Synonyms (68)

Synonym
AB00698516-09
81147-92-4
methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate
esmolol [inn:ban]
esmolol
C06980
103598-03-4
methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate
(+/-)-esmolol
DB00187
3-[4-(2-hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester
methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
(+/-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
brn 5287174
benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester
(+-)-esmolol
asl 8052-001
AC-12058
HMS2090P06
asl-8052-001
chebi:88206 ,
CHEMBL768
methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate
L001332
esmolol (inn)
D07916
NCGC00185766-02
AKOS015960734
bdbm50404796
unii-mdy902uxsr
mdy902uxsr ,
FT-0630886
S5778
gtpl7178
methyl 3-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)propanoate
sl-8052
esmolol [vandf]
esmolol [inn]
3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propionic acid methyl ester
esmolol [who-dd]
benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester, (+/-)-
esmolol [mi]
AB00698516-07
SCHEMBL3605
AC-35197
benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester
methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate
E1106
methyl 3-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]propionate
3-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]propionic acid methyl ester
AB00698516_10
(+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
DTXSID4022995 ,
SR-01000763706-3
MRF-0000253
NCGC00185766-05
Q418139
mfcd00864566
HMS3886F03
HMS3743M15
D90594
EN300-7384765
dtxcid702995
rac-methyl 3-(4-(2-hydroxy-3-(propan-2-ylamino)propoxy)phenyl)propanoate
3-(4-(2-hydroxy-3-isopropylamino-propoxy)-phenyl)-propionic acid methyl ester
chebi:4856
esmololum
c07ab09

Research Excerpts

Overview

Esmolol is a highly selective beta 1 receptor blocker with various effects such as slowing heart rate, lowering blood pressure and reducing myocardial oxygen consumption. It is an ultra-short-acting beta-blocker mostly used in emergency and high-risk patients.

ExcerptReferenceRelevance
"Esmolol is a common short-acting drug to control ventricular rate. "( Effect of Esmolol on Clinical Outcomes in Critically Ill Patients: Data from the MIMIC-IV Database.
An, S; Chen, K; Chen, Z; Deng, Z; Li, J; Li, L; Liang, Q; Zeng, Z; Zhou, S,
)
1.98
"Esmolol is a beta-1 selective blocker that has been shown to reduce postoperative pain. "( Intra-operative esmolol and pain following mastectomy: A randomised clinical trial.
de Carvalho, LSF; Mendonça, FT; Miake, HI; Seixas, LF; Sposito, AC; Tramontini, AJ, 2021
)
2.41
"Esmolol is a highly selective beta 1 receptor blocker with various effects such as slowing heart rate, lowering blood pressure and reducing myocardial oxygen consumption. "( Esmolol reduces apoptosis and inflammation in early sepsis rats with abdominal infection.
Dong, S; He, X; Lu, Y; Wang, D; Wang, W; Yang, Y; Zhang, P, 2017
)
3.34
"Esmolol is an ultrashort β-1 receptor antagonist. "( Intraoperative Esmolol as an Adjunct for Perioperative Opioid and Postoperative Pain Reduction: A Systematic Review, Meta-analysis, and Meta-regression.
Anderson, TA; Burns, SM; Gelineau, AM; Houle, T; King, MR; Ladha, KS, 2018
)
2.28
"Esmolol is an ultra-short-acting β"( Effects of esmolol on QTc interval changes during tracheal intubation: a systematic review.
Lee, JY; Sembu, M; Thiruvenkatarajan, V; Van Wijk, RM; Watts, R, 2019
)
2.35
"Esmolol is an ultra-short-acting beta-blocker mostly used in emergency and high-risk patients."( Esmolol reduces perioperative ischemia in cardiac surgery: a meta-analysis of randomized controlled studies.
Bignami, E; Crescenzi, G; Distaso, F; Landoni, G; Monaco, F; Oriani, A; Turi, S; Zangrillo, A, 2009
)
2.52
"Esmolol is a unique cardioselective β(1)-receptor blocking agent with a rapid onset and short duration of action. "( Clinical pharmacokinetics and therapeutic efficacy of esmolol.
Haney, JS; Wiest, DB, 2012
)
2.07
"Esmolol is a very short-acting beta-blocker commonly used in critically ill patients. "( Liquid chromatography-electrospray mass spectrometry (LC-MS) method for determination of esmolol concentration in human plasma.
Adamson, PC; Shi, H; Zuppa, AF, 2003
)
1.98
"Esmolol is a cardioselective beta-blocker with very rapid onset of action and short half-life due to its metabolism by blood-borne esterases. "( Successful treatment of long QT syndrome-induced ventricular tachycardia with esmolol.
Balcells, J; Iglesias, J; Pujol, M; Rodríguez, M,
)
1.8
"Esmolol is an ultra-short-term acting beta adrenergic blocker for intravenous use. "( The negative inotropic effect of esmolol on isolated cardiac muscle.
Arlock, P; Sjöberg, T; Steen, S; Wohlfart, B, 2005
)
2.05
"Esmolol is a unique cardioselective, intravenous, ultra-short acting, beta1-adrenergic blocking agent. "( Esmolol inhibits Na+ current in rat ventricular myocytes.
Deng, CY; Kuang, SJ; Lin, SG; Qian, WM; Shan, ZX; Wu, SL; Yang, M; Yu, XY; Zhang, WC, 2006
)
3.22
"Esmolol appears to be a helpful tool to avoid myocardial ischemia (e.g., in the perioperative setting)."( Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone.
Boldt, J; Suttner, S, 2007
)
1.32
"Esmolol is a new, highly efficient, cardioselective beta-adrenergic receptor blocking agent for intravenous use only. "( [Esmolol--beta-adrenergic blocking agent with ultrashort action].
Marenović, T; Marković, M; Stojiljković, MP, 1992
)
2.64
"Esmolol (ASL-8052) is a new intravenous beta-adrenergic blocking agent that has exhibited both cardiac selectivity and an extremely short half-life in animal studies. "( Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias.
Byrd, RC; Marks, J; Parmley, WW; Sung, RJ, 1984
)
2.02
"Esmolol is an ultra-short-acting beta-blocker currently in Phase II clinical trials. "( Gas chromatographic-mass spectrometric assay for the ultra-short-acting beta-blocker esmolol.
Sum, CY; Yacobi, A, 1984
)
1.93
"Esmolol is an ultra-short-acting beta blocker. "( Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite.
Davis, CS; Kartzinel, R; Lai, CM; Stampfli, H; Sum, CY; Yacobi, A, 1983
)
2.09
"Esmolol is a unique cardioselective, intravenous, ultra-short acting, beta-adrenergic blocking agent. "( Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Appunn, DO; Barbier, GH; Shettigar, UR, 1995
)
1.97
"Esmolol is an ultra short-acting intravenous cardioselective beta-antagonist. "( Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
Wiest, D, 1995
)
3.18
"Esmolol is a safe and efficacious beta-blocking agent in young patients."( Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.
Benson, DW; Blahunka, PC; Cuneo, BF; Zales, VR,
)
1.12
"Esmolol is an ultra-short-acting beta-blocker that is widely used to lower blood pressure in acute settings intraoperatively and in patients with hypertension. "( Beta-receptor antagonism does not fully explain esmolol-induced hypotension.
Deegan, R; Wood, AJ, 1994
)
1.99
"Esmolol is a cardioselective, ultrashort-acting beta adrenergic blocking agent with a very short half-life."( The effect of single bolus dose of esmolol for controlling the tachycardia and hypertension during laryngoscopy and tracheal intubation.
Chen, CS; Chia, YY; Haung, LH; Jan, KT; Kang, L; Wang, CH; Yuan, L, 1994
)
1.29
"Esmolol is an effective controlled agent for the treatment and prevention of supraventricular tachycardia and hyperdynamic reaction developing in cardiothoracic patients during anesthesia and surgery."( [Use of a new ultra short-acting beta adrenoblocker esmolol in anesthesiological practice].
Buniatian, AA; Flerov, EV; Poplavskiĭ, IV; Shitikov, II; Trekova, NA,
)
1.1
"Esmolol is a short-acting beta-blocker used during surgical procedures to reduce heart rate and blood pressure."( Evaluating a possible pharmacokinetic interaction between remifentanil and esmolol in the rat.
Eddington, ND; Haidar, SH; Hoke, JF; Liang, Z; Moreton, JE; Muir, KT, 1997
)
1.25
"Esmolol is a beta-adrenergic receptor antagonist with a relatively specific affinity for beta 1 adrenergic receptors. "( [Esmolol in anesthesiology: pharmacology and indications].
Fita, G; Gomar, C; Rovira, I, 1999
)
2.66
"Esmolol is a specific beta 1-blocker; it is hydrosoluble, without intrinsic sympathetic activity. "( [Characteristics and clinical use of esmolol].
Ravussin, P, 1992
)
2
"Esmolol is a new cardioselective beta blocker with unique pharmacokinetic properties resulting in a half-life of only 9 minutes. "( Usefulness of esmolol in unstable angina pectoris. European Esmolol Study Group.
Hohnloser, SH; Just, H; Klingenheben, T; Meinertz, T; Sydow, B, 1991
)
2.08
"Esmolol (Brevibloc) is a unique, short-acting beta blocker that is strongly beta 1 selective at usual clinical doses."( Esmolol and beta-adrenergic blockade.
Fiedler, MA; Wolman, RL, 1991
)
2.45
"Esmolol is a new ultra short-acting (half-life [t1/2] beta 9 min) beta 1-adrenergic-receptor antagonist reported to have no intrinsic sympathomimetic activity. "( Use of an ultra short-acting beta-blocker in patients with acute myocardial ischemia.
Antman, EM; Braunwald, E; Kirshenbaum, JM; Kloner, RA, 1985
)
1.71
"Esmolol is an ultrashort-acting beta blocker with a biologic half-life of 9 minutes."( Experimental and clinical observations on the efficacy of esmolol in myocardial ischemia.
Antman, EM; Braunwald, E; Kirshenbaum, J; Kloner, RA; Lange, R, 1985
)
1.23
"Esmolol is a beta 1-selective adrenoceptor blocker that is rapidly metabolized by blood and liver esterases. "( Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade.
Koshakji, RP; Reilly, CS; Wood, AJ; Wood, M, 1985
)
1.71
"Esmolol is an ultra-short-acting beta-adrenergic blocking agent that possesses minimal partial agonist activity or direct membrane depressant activity. "( Pharmacology and pharmacokinetics of esmolol.
Gorczynski, RJ; Quon, CY; Reynolds, RD, 1986
)
1.99
"Esmolol is a new ultra-short-acting beta-adrenergic receptor blocking agent that may be useful in the treatment of patients with heart disease. "( Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus.
Hulse, J; Pritchett, EL; Sintetos, AL, 1987
)
1.98
"Esmolol is an ultrashort-acting, cardioselective, intravenous beta-blocker with an elimination half-life of about nine minutes. "( Esmolol: a novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life.
Covinsky, JO, 1987
)
3.16
"Esmolol is a relatively cardioselective beta-adrenoceptor antagonist. "( Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Benfield, P; Sorkin, EM, 1987
)
3.16
"Esmolol (Brevibloc) is an intravenous, short-acting, titratable, cardioselective beta blocker with a very rapid onset and offset of action (t1/2 = 9.2 minutes). "( Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
Laddu, A; Lee, R; Murthy, VS; Singh, B; Turlapaty, P, 1987
)
3.16
"Esmolol is a new intravenous beta-adrenergic blocker with an ultrashort (nine-minute) elimination half-life, which has been studied predominantly for control of supraventricular tachycardia and management of certain types of hypertension. "( Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
Gray, RJ, 1988
)
1.99
"Esmolol (Brevibloc) is a potent, titratable, cardioselective beta-blocker with a short elimination half-life (t1/2 = 9.2 min) and no intrinsic sympathomimetic activity. "( Esmolol: a short-acting titratable beta-blocker in acute myocardial ischemia.
Laddu, A; Turlapaty, P; Viray, R, 1988
)
3.16
"Esmolol is an ester and is metabolized by choline-esterase to ASL 8123, an inactive molecule."( Controlled beta-receptor blockade with esmolol and flestolol.
Frishman, WH; Murthy, VS, 1988
)
1.27
"Esmolol is a rapidly metabolized cardioselective beta-adrenergic blocker that provides steady state beta-adrenergic blockade when administered by continuous intravenous infusion. "( Safety and efficacy of esmolol for unstable angina pectoris.
Littman, WJ; Pope, C; Scanlon, PJ; Wallis, DE, 1988
)
2.03
"Esmolol is an intravenous beta blocker with a short duration of action. "( Pharmacokinetics of esmolol in hepatic disease.
Achari, R; Buchi, KN; Drissel, D; Hulse, JD; Rollins, DE; Tolman, KG, 1987
)
2.04
"Esmolol (E) is a new, intravenous, rapidly metabolized beta blocker."( Heart rate and blood pressure effects of esmolol after ketamine induction and intubation.
Brown, M; Coverman, S; Gold, MI; Herrington, C, 1986
)
1.26
"Esmolol is an investigational ultra-short-acting beta-adrenergic blocker that has potential application in many clinical cardiology settings. "( Effects of bolus injection of esmolol in healthy, exercising subjects.
Ellenbogen, KA; McCarthy, EA; Pritchett, EL, 1987
)
2

Effects

Esmolol has a tissue distribution time of 2 minutes and an elimination half-life of 9 minutes. It has a positive effect on the cardiac recovery in cardiopulmonary bypass surgeries.

Esmolol has been proposed as a viable adjunctive therapy for pre-hospital refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT) It has an elimination half-life of nine minutes which accounts for its ultrashort duration of action.

ExcerptReferenceRelevance
"Esmolol has a beneficial effect on the T helper 1/T helper 2 balance in patients with heart failure. "( The immunomodulatory role of esmolol in patients undergoing laparoscopic gastrectomy due to gastric cancer.
Cho, ML; Her, YM; Huh, JW; Kang, SH; Kim, YS; Lee, J; Song, KY, 2013
)
2.12
"Esmolol has a positive effect on the cardiac recovery in cardiopulmonary bypass surgeries."( Effect of short-acting beta blocker on the cardiac recovery after cardiopulmonary bypass.
Ding, Z; Qian, Y; Sun, J, 2011
)
1.81
"Esmolol has a tissue distribution time of 2 minutes and an elimination half-life of 9 minutes."( Evaluation of esmolol and fentanyl in controlling increases in heart rate and blood pressure during endotracheal intubation.
Gaubatz, CL; Wehner, RJ, 1991
)
1.36
"Esmolol has a rapid onset and short duration of effect."( Cardiovascular effects of esmolol in anesthetized humans.
Alvis, JM; Bradley, E; Govier, AV; Henling, CE; Kissin, I; Lell, WA; Menkhaus, PG; Reves, JG; Samuelson, PN, 1985
)
1.29
"Esmolol has an elimination half-life of nine minutes which accounts for its ultrashort duration of action."( Controlled beta-receptor blockade with esmolol and flestolol.
Frishman, WH; Murthy, VS, 1988
)
1.27
"Esmolol has been proposed as a viable adjunctive therapy for pre-hospital refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT)."( Esmolol in the management of pre-hospital refractory ventricular fibrillation: A systematic review and meta-analysis.
Alonso, W; Miguel, LA; Miraglia, D, 2020
)
3.44
"Esmolol has been used widely for its chronotropic and antihypertensive effects."( Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care.
Bahr, MP; Williams, BA, 2018
)
2.64
"Esmolol has a beneficial effect on the T helper 1/T helper 2 balance in patients with heart failure. "( The immunomodulatory role of esmolol in patients undergoing laparoscopic gastrectomy due to gastric cancer.
Cho, ML; Her, YM; Huh, JW; Kang, SH; Kim, YS; Lee, J; Song, KY, 2013
)
2.12
"Esmolol has a positive effect on the cardiac recovery in cardiopulmonary bypass surgeries."( Effect of short-acting beta blocker on the cardiac recovery after cardiopulmonary bypass.
Ding, Z; Qian, Y; Sun, J, 2011
)
1.81
"Esmolol has neuroprotective effects in the acute phase of ischemia by a mechanism other than shortening the duration of ischemic depolarization."( Quantitative evaluation of the neuroprotective effects of a short-acting β-adrenoceptor antagonist at a clinical dose on forebrain ischemia in gerbils: effects of esmolol on ischemic depolarization and histologic outcome of hippocampal CA1.
Danura, T; Mizoue, R; Morita, K; Naito, H; Sato, S; Shiraishi, K; Takeda, Y, 2013
)
2.03
"Esmolol also has been used for treatment of perioperative hypertension and for reducing cardiac work in patients with ischemic heart disease."( [New ultra-short-acting beta-blockers: landiolol and esmolol--the effects on cardiovascular system].
Mio, Y, 2006
)
1.3
"Esmolol has been studied and applied to control hypertension and tachycardia during open heart surgery. "( Esmolol cardioplegia in unstable coronary revascularisation patients. A randomised clinical trial.
Harmoinen, A; Kaukinen, S; Rinne, T, 2000
)
3.19
"Esmolol has to be given either as a mini-infusion at a rate of 300-600 micrograms/kg/min for the first 1-2 minutes followed by 200-300 micrograms/Kg/min or as a bolus (just before a nociceptive stimulus) 1-3 mg/kg."( [Characteristics and clinical use of esmolol].
Ravussin, P, 1992
)
1.28
"Esmolol has a tissue distribution time of 2 minutes and an elimination half-life of 9 minutes."( Evaluation of esmolol and fentanyl in controlling increases in heart rate and blood pressure during endotracheal intubation.
Gaubatz, CL; Wehner, RJ, 1991
)
1.36
"Esmolol has been used to improve hemodynamic stability during sternotomy and aortic manipulation for coronary artery bypass graft surgery. "( Influence of temperature on in vitro metabolism of esmolol.
Delphin, E; Melendez, JA; Quon, CY; Stone, JG, 1990
)
1.97
"Esmolol has a rapid onset and short duration of effect."( Cardiovascular effects of esmolol in anesthetized humans.
Alvis, JM; Bradley, E; Govier, AV; Henling, CE; Kissin, I; Lell, WA; Menkhaus, PG; Reves, JG; Samuelson, PN, 1985
)
1.29
"Esmolol has been shown to be safe and efficacious in patients in ASA classifications I through IV and patients undergoing carotid endarterectomy and coronary artery bypass surgery."( Perioperative use of esmolol.
Flezzani, P; Reves, JG, 1985
)
1.31
"Esmolol has been generally well tolerated, and although hypotension has occurred in up to 44% of patients it resolved during or soon after the infusion of esmolol."( Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Benfield, P; Sorkin, EM, 1987
)
2.44
"Esmolol has also been shown to be effective and safe in attenuating the tachycardia and hypertension seen during the intraoperative period."( Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
Laddu, A; Lee, R; Murthy, VS; Singh, B; Turlapaty, P, 1987
)
2.44
"Esmolol also has been shown to control heart rate and blood pressure during episodes of acute myocardial ischemia."( Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
Gray, RJ, 1988
)
1.27
"Esmolol has an elimination half-life of nine minutes which accounts for its ultrashort duration of action."( Controlled beta-receptor blockade with esmolol and flestolol.
Frishman, WH; Murthy, VS, 1988
)
1.27

Actions

Esmolol can suppress inflammation and apoptosis in the intestinal tissue via the overexpression of NF-kappa B-p65 in the early stage sepsis rats. The esmolol group had lower scores on a pain numerical rating scale and required less fentanyl in the Postanesthesia Care Unit.

ExcerptReferenceRelevance
"Esmolol can suppress inflammation and apoptosis in the intestinal tissue via the overexpression of NF-kappa B-p65 in the early stage sepsis rats. "( Esmolol inhibits inflammation and apoptosis in the intestinal tissue via the overexpression of NF-κB-p65 in the early stage sepsis rats.
An, H; Guo, CA; Liu, HB; Ma, L; Su, XL; Wang, YZ; Zhang, B; Zhen, LL, 2020
)
3.44
"The esmolol group had lower scores on a pain numerical rating scale and required less fentanyl in the Postanesthesia Care Unit."( The effect of a continuous infusion of low-dose esmolol on the requirement for remifentanil during laparoscopic gynecologic surgery.
Cho, SJ; Hwang, WJ; Lee, J; Moon, YE, 2013
)
1.13
"Esmolol resulted in a lower peak DeltaPV (6.4 +/- 2.0 mL kg(-1)) and a negative DeltaPV (-0.4 +/- 0.6 mL kg(-1)) at study's end."( Effect of esmolol on fluid therapy in normovolemia and hypovolemia.
Kinsky, MP; Kramer, GC; Prough, DS; Vaid, SU; Vane, LA, 2008
)
1.47
"Esmolol, because of its ultrashort action, cardioselective properties and titratability, has been shown to be safe and effective for the treatment of tachycardia and hypertension."( Clinical pharmacology of alpha2-agonist and beta-adrenergic blocker.
Franz, DN; Tseng, J; Wong, KC, 1989
)
1
"Esmolol, because of its ultrashort duration of action, should be safe for the induction of beta blockade in patients who are critically ill and is ideally suited for rapidly changing levels of beta blockade in this clinical situation."( Basic pharmacology of esmolol.
Gorczynski, RJ, 1985
)
1.31

Treatment

Pretreatment with esmolol and fentanyl resulted in significant attenuation of the norepinephrine peak after seizure. Esmolol treatment may be able to improve survival rate, and reduce heart rate and TnI, but has no influence on MAP, CVP and ScvO2.

ExcerptReferenceRelevance
"Esmolol-treated patients were associated with higher extubation quality compared to patients who received placebo (p...<...0.001), with an approximately two-fold increase in the rate of patients without cough (91.1%) in the esmolol group compared to the placebo group (46.7%)."( Efficacy of a single dose of esmolol to prevent extubation-related complications during emergence from anesthesia: a randomized, double-blind, placebo-controlled trial.
Barreto Filho, JH; Hungria, MBCS; Magalh Es, TC; Mendon A, FÍT,
)
1.14
"Esmolol treatment may be safe and effective in decreasing 28-day mortality, controlling heart rate, and providing cardioprotective function, but has no effect on lung injury in patients with sepsis or septic shock after early fluid resuscitation. "( Benefits of esmolol in adults with sepsis and septic shock: An updated meta-analysis of randomized controlled trials.
Chen, C; Liu, Y; Yang, J; Yang, X; Yang, Y; Zhang, J, 2022
)
2.54
"Esmolol as one treatment of sepsis induced cardiomyopathy (SIC) is still controversial. "( Evaluating the effects of Esmolol on cardiac function in patients with Septic cardiomyopathy by Speck-tracking echocardiography-a randomized controlled trial.
Gao, X; He, Z; Li, T; Wang, J; Xu, G, 2023
)
2.65
"Esmolol treatment was associated with reduced heart rate and lowered DBP and MAP, which may increase vasopressor use and fluid balance at the timepoint of 24 hours in critically ill patients during ICU stay. "( Effect of Esmolol on Clinical Outcomes in Critically Ill Patients: Data from the MIMIC-IV Database.
An, S; Chen, K; Chen, Z; Deng, Z; Li, J; Li, L; Liang, Q; Zeng, Z; Zhou, S,
)
1.98
"In esmolol-treated pigs, the diagnostic ability of HR was decreased (AUC = 0.766 and 0.733)."( Pulse Oximeter Plethysmograph Variation During Hemorrhage in Beta-Blocker-Treated Swine.
Cho, WS; Jung, YS; Kang, MW; Kim, KS; Kim, T; Kwon, WY; Lee, B; Lee, JC; Lee, MS; Shin, SM; Suh, GJ, 2020
)
1.07
"Esmolol pretreatment effectively attenuated desflurane-induced HR increase."( Esmolol pretreatment attenuates heart rate increase and parasympathetic inhibition during rapid increases in desflurane concentration: A preliminary randomized study.
Chan, HL; Kao, MC; Tzeng, IS, 2017
)
2.62
"Esmolol pretreatment attenuates HR increase and parasympathetic inhibition during rapid increases in desflurane concentration."( Esmolol pretreatment attenuates heart rate increase and parasympathetic inhibition during rapid increases in desflurane concentration: A preliminary randomized study.
Chan, HL; Kao, MC; Tzeng, IS, 2017
)
3.34
"Esmolol treatment may be able to improve survival rate, and reduce heart rate and TnI, but has no influence on MAP, CVP and ScvO2 in patients with septic shock and sepsis."( The influence of esmolol on septic shock and sepsis: A meta-analysis of randomized controlled studies.
Feng, M; Liu, P; Tang, Y; Wu, Q; Zhou, Z, 2018
)
2.26
"esmolol pretreatment on propofol injection pain."( Pretreatment with a very low dose of intravenous esmolol reduces propofol injection pain.
Akgün Salman, E; Akpek, E; Arslan, G; Titiz, L, 2013
)
1.37
"Esmolol treatment statistically significantly decreased troponin T, CK, CK-MB and NT-proBNP release as surrogate markers for myocardial injury in patients with STEMI. "( Randomized Control of Sympathetic Drive With Continuous Intravenous Esmolol in Patients With Acute ST-Segment Elevation Myocardial Infarction: The BEtA-Blocker Therapy in Acute Myocardial Infarction (BEAT-AMI) Trial.
Biesenbach, E; Caglayan, E; Dahlem, KM; Er, F; Eran-Ergöknil, A; Erdmann, E; Gassanov, N; Hellmich, M; Herrfurth, T; Kuhr, K; Le, MT; Nia, AM; Taghiyev, Z; Vanezi, M; Waltenberger, J; Yüksel, D, 2016
)
2.11
"Esmolol treatment also abated the increase in bronchoalveolar lavage fluid protein and proinflammatory cytokines."( Esmolol attenuates lung injury and inflammation in severe acute pancreatitis rats.
Ke, L; Li, J; Li, W; Nie, Y; Tong, Z; Zhang, L; Zheng, Y,
)
2.3
"For esmolol-treated patients mean baseline and acquisition HR were 74±14 bpm and 63±9 bpm, respectively (p<0.001)."( Bailout intravenous esmolol for heart rate control in cardiac computed tomography angiography.
Aguiar Rosa, S; Casado, H; Cruz Ferreira, R; Figueiredo, L; Leal, C; Marques, H; Ramos, R; Santos, R; Saraiva, M, 2016
)
1.24
"Esmolol-treated patients had more episodes of bradycardia (19/129 [14.72%] v 3/133 [2.25%], OR = 5.49 [2.21-13.62], p = 0.0002) and hypotension (28/113 [24.77%] v 14/119 [11.76%], OR = 2.73 [0.83-9.04], p = 0.10)."( Esmolol reduces perioperative ischemia in cardiac surgery: a meta-analysis of randomized controlled studies.
Bignami, E; Crescenzi, G; Distaso, F; Landoni, G; Monaco, F; Oriani, A; Turi, S; Zangrillo, A, 2009
)
2.52
"Esmolol-treated patients did not experience more episodes of hypotension (17/384 [4.42%] v 38/439 [8.65%], OR = 0.41 [0.22-0.79], p = 0.17) and bradycardia (25/342 [7.30%] v 17/406 [4.18%], OR = 1.42 [0.74-2.74], p = 0.42)."( Esmolol reduces perioperative ischemia in noncardiac surgery: a meta-analysis of randomized controlled studies.
Belloni, I; Bignami, E; Biondi-Zoccai, G; Cornero, G; Landoni, G; Testa, V; Turi, S; Zangrillo, A, 2010
)
2.52
"In esmolol-treated animals, cardiac index decreased by 9% at T + 180 min and by 2% at T + 300 min, and in controls by 14% at T + 180 min and by 27% at T + 300 min (p = 0.870)."( Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock.
Aboab, J; Annane, D; Gharbi, M; Jourdain, M; Mangalaboyi, J; Mansart, A; Sebille, V, 2011
)
1.27
"Esmolol-treated animals required a significantly smaller number of electrical shocks before resuscitation. "( Beta1-adrenergic blockade during cardiopulmonary resuscitation improves survival.
Cammarata, G; Huang, L; Sun, S; Tang, W; Wang, J; Weil, MH, 2004
)
1.77
"Esmolol treated patients had significantly lower in-hospital mortality (p<0.02), less frequently had postinfarction angina (p<0.05) and heart failure progression (p<0.01) and demonstrated significant decrease of brain natriuretic peptide level (by 25%, p<0.05)."( [The use of esmolol in patients with myocardial infarction complicated with acute left ventricular failure].
Dzhaiani, NA; Golubev, AV; Kochetov, AG; Kositsyna, IV; Tereshchenko, SN, 2005
)
1.43
"Esmolol-treated hearts showed better recovery than those receiving potassium, in terms of +/- dP/dt (p < 0.01), left ventricular systolic pressure (p < 0.01), and left ventricular developed pressure (p < 0.009)."( Beyond hyperkalemia: beta-blocker-induced cardiac arrest for normothermic cardiac operations.
Deslauriers, R; Ede, M; Gregorash, L; LeHouerou, D; Lessana, A; Pargaonkar, S; Salerno, TA; Summers, R; Ye, J, 1997
)
1.02
"Esmolol-treated patients also reported less sedation in the first 15 min of recovery than those receiving alfentanil."( Efficacy of esmolol versus alfentanil as a supplement to propofol-nitrous oxide anesthesia.
Smith, I; Van Hemelrijck, J; White, PF, 1991
)
1.38
"With esmolol treatment, the difficulties of therapy with long-lasting beta blockers are avoided."( Perioperative use of esmolol.
Flezzani, P; Reves, JG, 1985
)
1.04
"Treatment with esmolol decreased the inflammatory response and CRP production in a dose-dependent manner."( The effects of intraoperative esmolol administration on perioperative inflammatory responses in patients undergoing laparoscopic gastrectomy: a dose-response study.
Ahn, S; Cho, ML; Her, YM; Hwang, W; Kim, Y; Lee, J, 2015
)
1.05
"Treatment with esmolol was associated with improved survival time (11.1 ± 1.6 h vs. "( Esmolol attenuates lung injury and inflammation in severe acute pancreatitis rats.
Ke, L; Li, J; Li, W; Nie, Y; Tong, Z; Zhang, L; Zheng, Y,
)
1.93
"Pretreatment with esmolol 0.5 mg/kg and 1 mg/kg and remifentanil 0.35 μg/kg equally decreased pain during propofol injection."( Comparative evaluation of the effect of remifentanil and 2 different doses of esmolol on pain during propofol injection: A double-blind, randomized clinical consort study.
Jeon, Y; Kim, S; Kwon, T; Lee, M; Park, K, 2017
)
1.02
"Treatment with esmolol (500 microg/kg in bolus maintained at a mean rate of 200 +/- 50 microg/kg per min) effectively controlled hypertension and tachycardia in 45 of 49 patients (92%; P < 0.05) within a mean 4.30 +/- 2.20 minutes."( Esmolol blunts postoperative hemodynamic changes after propofol-remifentanil total intravenous fast-track neuroanesthesia for intracranial surgery.
Bilotta, F; Cuzzone, V; Delfini, R; Doronzio, A; Lam, AM; Rosa, G, 2008
)
2.13
"Pre-treatment with esmolol infusion prevented the above haemodynamic changes, allowing successful extubation."( Esmolol facilitated extubation in a patient with severe systolic dysfunction following myocardial infarction.
Arapi, S; Griva, X; Karavidas, A; Lazaros, G; Matsakas, E,
)
1.89
"Treatment with esmolol failed to completely prevent an increase in blood pressure, but she did well nonetheless."( ECT in the presence of intracranial aneurysm.
Guttmacher, LB; Najjar, F, 1998
)
0.64
"Pretreatment with esmolol and fentanyl resulted in significant attenuation of the norepinephrine peak after seizure (P less than 0.05)."( Prevention of the cardiovascular and neuroendocrine response to electroconvulsive therapy: II. Effects of pretreatment regimens on catecholamines, ACTH, vasopressin, and cortisol.
Brown, M; Hauger, R; Mirow, A; Partridge, BL; Weinger, MB, 1991
)
0.6
"Treatment with esmolol 200 mg resulted in a significantly shorter mean seizure duration than with placebo."( Comparison of two esmolol bolus doses on the haemodynamic response and seizure duration during electroconvulsive therapy.
Arakawa, K; Goto, H; Kovac, AL; Pardo, MP, 1991
)
0.95
"Pretreatment with esmolol and labetalol significantly reduced the hemodynamic response to ECT, compared with fentanyl, lidocaine, or saline solution (P less than 0.05)."( Prevention of the cardiovascular and neuroendocrine response to electroconvulsive therapy: I. Effectiveness of pretreatment regimens on hemodynamics.
Hauger, R; Mirow, A; Partridge, BL; Weinger, MB, 1991
)
0.6

Toxicity

Intravenous esmolol, amiodarone and diltiazem are all equally effective and safe on controlling rapid ventricular rate in patients with atrial fibrillation during the anesthesia period. HR control was much less effective in the postoperative period. Esmolol is safe when used at recommended doses.

ExcerptReferenceRelevance
" We report the case of a patient suffering from an acute, intentional theophylline overdose who exhibited the classic features of a toxic ingestion and describe the first reported use of IV esmolol in the treatment of accompanying cardiovascular manifestations."( Acute theophylline toxicity and the use of esmolol to reverse cardiovascular instability.
Friedman, B; Scott, J; Seneff, M; Smith, M, 1990
)
0.73
" The most prevalent adverse effect during esmolol infusion was hypotension which occurred in eight patients (12%)."( Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
Anderson, S; Blanski, L; Byrd, RC; Das, G; Engler, R; Laddu, A; Lee, R; Rajfer, S; Schroeder, J; Steck, JD, 1986
)
0.8
" Most patients at risk for adverse effects during beta blockade (i."( Intravenous esmolol for the treatment of supraventricular tachyarrhythmia: results of a multicenter, baseline-controlled safety and efficacy study in 160 patients. The Esmolol Research Group.
, 1986
)
0.65
" The only adverse effect seen was hypotension in 2 patients."( Safety and efficacy of flestolol, a new ultrashort-acting beta-adrenergic blocking agent, for supraventricular tachyarrhythmias.
Burge, J; Katz, RJ; Keefe, D; Laddu, AR; Somberg, JC; Steinberg, JS, 1986
)
0.27
" The principal adverse effect was hypotension, reported in 23 esmolol (asymptomatic in 19) and four propranolol (asymptomatic in three) patients."( Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial.
Abrams, J; Allen, J; Allin, D; Anderson, J; Anderson, S; Blanski, L; Chadda, K; DiBianco, R; Favrot, L; Gonzalez, J, 1985
)
0.82
" Twenty-eight patients (25 percent) developed dose-limiting adverse effects during esmolol maintenance infusions."( Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
Hilleman, DE; Hunter, CB; Mohiuddin, SM; Mooss, AN, 1994
)
0.92
"To determine (1) if perioperative use of esmolol in major vascular surgery patients provides strict heart rate (HR) control, (2) what doses of esmolol are required to do this, and (3) does this control influence myocardial ischemia or result in adverse consequences."( The safety and effectiveness of esmolol in the perioperative period in patients undergoing abdominal aortic surgery.
Butterworth, J; Dean, R; Hansen, K; Harwood, TN; Plonk, G; Prielipp, RC; Royster, RL, 1999
)
0.85
"Only one patient demonstrated an adverse effect."( The safety and effectiveness of esmolol in the perioperative period in patients undergoing abdominal aortic surgery.
Butterworth, J; Dean, R; Hansen, K; Harwood, TN; Plonk, G; Prielipp, RC; Royster, RL, 1999
)
0.59
" HR control was much less effective in the postoperative period, but esmolol is safe when used at recommended doses."( The safety and effectiveness of esmolol in the perioperative period in patients undergoing abdominal aortic surgery.
Butterworth, J; Dean, R; Hansen, K; Harwood, TN; Plonk, G; Prielipp, RC; Royster, RL, 1999
)
0.82
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"Intravenous esmolol is safe and effective to reach the optimum heart rate in patients assigned for MSCT."( Safety and efficacy of patient preparation with intravenous esmolol before 64-slice computed tomography coronary angiography.
Aytaclar, S; Bayrak, F; Degertekin, M; Gemici, G; Guneysu, T; Kaya, Z; Mutlu, B; Sevinc, D, 2008
)
0.97
" All dose groups showed similar incidences of adverse events."( The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: a multicenter, double-blind, randomized trial.
Adamson, PC; Backer, CL; Bokesch, P; Hoffman, ML; McGowan, FX; Nicolson, SC; Schreiner, M; Tabbutt, S; Tweddell, JS; Wells, W; Zhang, X, 2008
)
0.6
"This review suggests that titration of esmolol to a hemodynamic end point can be safe and effective."( The safety of perioperative esmolol: a systematic review and meta-analysis of randomized controlled trials.
Beattie, WS; Karkouti, K; McCluskey, S; Tait, G; Wijeysundera, D; Yu, SK, 2011
)
0.93
" The incidence of total side effect was significantly lower in group II (10%) than in group I (16."( [A comparative study on the efficacy and safety of intravenous esmolol, amiodarone and diltiazem for controlling rapid ventricular rate of patients with atrial fibrillation during anesthesia period].
Shen, SL; Zhao, YC, 2010
)
0.6
"Intravenous esmolol, amiodarone and diltiazem are all equally effective and safe on controlling rapid ventricular rate in patients with atrial fibrillation during the anesthesia period."( [A comparative study on the efficacy and safety of intravenous esmolol, amiodarone and diltiazem for controlling rapid ventricular rate of patients with atrial fibrillation during anesthesia period].
Shen, SL; Zhao, YC, 2010
)
0.98
"The combination therapy with M + E produces a minimal change in hemodynamics and appears safe as an adjunctive therapy to PCI in AMI patients."( Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction.
Chan, KH; Chan, MY; Fujise, K; Huang, MH; Lee, CH; Low, AF; Lui, CY; Nguyen, V; Poh, KK; Sia, W; Tan, HC; Tang, LQ; Tay, EL; Xu, X, 2014
)
0.66
" Clinical course of patients, hemodynamics, days of hospitalization, LV function, and adverse events at follow-up were recorded."( Hemodynamic Effects, Safety, and Feasibility of Intravenous Esmolol Infusion During Takotsubo Cardiomyopathy With Left Ventricular Outflow Tract Obstruction: Results From A Multicenter Registry.
Biase, MD; Brunetti, ND; Caldarola, P; Fanelli, M; Ferraretti, A; Gennaro, LD; Ieva, R; Martino, LD; Musaico, F; Santoro, F; Tarantino, N, 2016
)
0.68
" No adverse events were observed during hospitalization and at follow-up."( Hemodynamic Effects, Safety, and Feasibility of Intravenous Esmolol Infusion During Takotsubo Cardiomyopathy With Left Ventricular Outflow Tract Obstruction: Results From A Multicenter Registry.
Biase, MD; Brunetti, ND; Caldarola, P; Fanelli, M; Ferraretti, A; Gennaro, LD; Ieva, R; Martino, LD; Musaico, F; Santoro, F; Tarantino, N, 2016
)
0.68
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Eligible randomized controlled studies (RCTs) reported a perioperative esmolol intervention with at least one of the primary (major cardiac or renal complications during the first 30 postoperative days) or secondary (postoperative adverse effects and all-cause mortality) outcomes."( Efficacy and safety of intravenous esmolol for cardiac protection in non-cardiac surgery. A systematic review and meta-analysis.
Ollila, A; Pettilä, V; Sund, R; Vikatmaa, L; Wilkman, E, 2019
)
1.02

Pharmacokinetics

Esmolol was not significantly altered by renal failure. Landiolol turned out to be superior to esmolol with respect to pharmacokinetic and pharmacodynamic profile and local tolerability.

ExcerptReferenceRelevance
" Serial esmolol blood samples were obtained for pharmacokinetic analysis."( Pharmacokinetics of esmolol in children.
Garner, SS; Gillette, PC; Trippel, DL; Wiest, DB, 1991
)
1.04
" The pharmacokinetic disposition of esmolol was not significantly altered by renal failure."( Pharmacokinetics of esmolol and ASL-8123 in renal failure.
Flaherty, JF; Gambertoglio, JG; Hulse, JD; La Follette, G; Warnock, DG; Wong, B, 1989
)
0.88
"The clinical pharmacology and pharmacodynamic data from several clinical trials are summarized."( Clinical pharmacology, pharmacodynamics and interactions with esmolol.
Bies, CM; Lowenthal, DT; Porter, RS; Saris, SD; Slegowski, MB; Staudacher, A, 1985
)
0.51
" The duration of action and elimination half-life both averaged less than 15 min."( Pharmacodynamics and onset of action of esmolol in anesthetized dogs.
Gorczynski, RJ; Quon, CY, 1986
)
0.54
" Esmolol did not consistently affect any other pharmacodynamic variable."( Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus.
Hulse, J; Pritchett, EL; Sintetos, AL, 1987
)
1.45
"beta-Adrenergic blocking agents--esmolol hydrochloride, pharmacokinetic profile, metabolism."( Esmolol: a pharmacokinetic profile of a new cardioselective beta-blocking agent.
Kartzinel, R; Lai, CM; Sum, CY; Yacobi, A, 1983
)
1.99
" It has an extremely short elimination half-life (mean: 9 minutes; range: 4 to 16 minutes) and a total body clearance [285 ml/min/kg (17."( Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
Wiest, D, 1995
)
1.73
"Esmolol, a short-acting intravenous cardioselective beta-blocking agent, was evaluated for age-dependent pharmacodynamic and pharmacokinetic features in 17 young patients (6 months to 14 years)."( Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.
Benson, DW; Blahunka, PC; Cuneo, BF; Zales, VR,
)
1.84
" A linked sigmoid Emax PK-PD model was used and the pharmacodynamic parameters were not statistically different."( The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat.
Eddington, ND; Haidar, SH; Hoke, JF; Liang, Z; Moreton, JE; Muir, KT, 1997
)
0.51
"At the doses tested, there is no pharmacokinetic or pharmacodynamic interaction between remifentanil and esmolol in the rat."( The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat.
Eddington, ND; Haidar, SH; Hoke, JF; Liang, Z; Moreton, JE; Muir, KT, 1997
)
0.73
" As a class, the beta blockers are quite diverse from a pharmacokinetic perspective, as they display a high range of values in plasma protein binding, percent of drug eliminated by metabolism or unchanged in the urine, and in hepatic extraction ratio."( Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
Brocks, DR; Mehvar, R,
)
0.13
"Esmolol is often used in the acute management of children with arrhythmias and/or hypertension; however, pharmacokinetic studies of the drug in children have been limited."( The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias.
Adamson, PC; Boston, R; Dick, M; Epstein, MR; Moate, P; Rhodes, LA; Saul, JP; Schreiner, MS,
)
1.88
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The pharmacokinetic estimates for esmolol showed a shorter elimination half-life (t(½)) [2."( Clinical pharmacokinetics and therapeutic efficacy of esmolol.
Haney, JS; Wiest, DB, 2012
)
0.9
" Landiolol turned out to be superior to esmolol with respect to pharmacokinetic and pharmacodynamic profile and local tolerability."( Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites.
Hodisch, J; Husch, B; Kadlecová, P; Krumpl, G; Maurer, G; Trebs, M; Ulč, I, 2018
)
0.97

Compound-Compound Interactions

Nicardipine combined with esmolol (1:10) regimen may maintain systemic and tissue oxygenation during OPCABG. Inotropic therapy with the PDE III inhibitor enoximone combined with tight HR control by a continuous infusion of Esmolol improved cardiac function.

ExcerptReferenceRelevance
"The primary objective of this study was to determine the effect of esmolol, administered alone and in combination with lidocaine, on ventricular fibrillation threshold (VFT) in pigs."( Antifibrillatory effect of esmolol alone and in combination with lidocaine.
Chow, MS; Colucci, RD; Fan, CD; Kluger, J; Sun, H; Tisdale, JE; Zhao, H, 1996
)
0.83
"9 years; 11/30 patients aged <6 months) underwent open heart procedures on the beating heart for simple and complex cardiac malformations using a self designed perfusion system with pressure- and volume-controlled continuous hypothermic coronary perfusion (PVC-CONTHY-CAP) in combination with ultra-short beta1-receptor blockade (Esmolol) and nitroglycerine for myocardial protection."( Myocardial protection by pressure- and volume-controlled continuous hypothermic coronary perfusion in combination with Esmolol and nitroglycerine for correction of congenital heart defects in pediatric risk patients.
Borowski, A; Eichstaedt, HC; Korb, H; Raji, MR; Schickendantz, S, 1998
)
0.68
" We report the use of a short-acting intravenous beta blocker in combination with inotropic therapy as a means to bridge five patients with advanced heart failure to chronic oral beta blockade; two of these patients had been chronically managed with intravenous inotrope."( Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure.
Hauptman, PJ; Prirzker, MR; Woods, D, 2002
)
0.31
" This study aimed at investigating whether or not nicardipine combined with esmolol (1:10) can maintain systemic and tissue oxygenation during OPCABG."( Effect of nicardipine combined with esmolol on systemic and tissue oxygenation during off-pump coronary artery bypass grafting surgery.
Jiang, Y; Wang, TL; Yang, BX, 2005
)
0.83
"Twenty patients scheduled for OPCABG were divided ramdomly into Group nicardipine (N) and Group nitroglycerine (X) respectively combined with esmolol (E) (Dosage ratio: 1 to 10) (Group N + E and Group X + E) with 10 patients in each group."( Effect of nicardipine combined with esmolol on systemic and tissue oxygenation during off-pump coronary artery bypass grafting surgery.
Jiang, Y; Wang, TL; Yang, BX, 2005
)
0.8
"Nicardipine combined with esmolol (1:10) regimen may maintain systemic and tissue oxygenation during OPCABG."( Effect of nicardipine combined with esmolol on systemic and tissue oxygenation during off-pump coronary artery bypass grafting surgery.
Jiang, Y; Wang, TL; Yang, BX, 2005
)
0.9
"Levosimendan, a calcium sensitizer, was used in combination with beta-adrenergic antagonists in a man aged 56 yr with cardiogenic shock, complicating acute myocardial infarction, who developed severe tachycardia after dobutamine administration."( Treatment of cardiogenic shock with levosimendan in combination with beta-adrenergic antagonists.
Alhashemi, JA, 2005
)
0.33
"It is possible to perform acute normovolemic hemodilution (ANH) in combination with controlled hypotension (CH)."( The effect of esmolol-induced controlled hypotension in combination with acute normovolemic hemodilution on cerebral oxygenation.
Bahk, JH; Do, SH; Han, SH; Kim, JH; Lim, YJ; Park, CD; Park, YS, 2006
)
0.69
"Fifty-six patients undergoing major orthopedic surgery were randomly assigned to either group A (ANH only) or group CH (CH in combination with ANH)."( The effect of esmolol-induced controlled hypotension in combination with acute normovolemic hemodilution on cerebral oxygenation.
Bahk, JH; Do, SH; Han, SH; Kim, JH; Lim, YJ; Park, CD; Park, YS, 2006
)
0.69
"ANH in combination with esmolol-induced CH causes a significant decrease in cerebral oxygen saturation compared with ANH alone."( The effect of esmolol-induced controlled hypotension in combination with acute normovolemic hemodilution on cerebral oxygenation.
Bahk, JH; Do, SH; Han, SH; Kim, JH; Lim, YJ; Park, CD; Park, YS, 2006
)
1
"The aim of this study was to assess cardiac function in vascular surgery patients with known coronary artery disease (CAD) who received continuous perioperative beta blocker therapy with esmolol alone versus esmolol in combination with the phosphodiesterase (PDE) III inhibitor enoximone."( [Continuous beta-block with esmolol in combination with enoximone: influence on cardiac function in high risk patients undergoing vascular surgery].
Boldt, J; Lang, K; Mayer, J; Piper, SN; Röhm, K; Suttner, S, 2008
)
0.83
"Over a period of 24 h, 28 patients were assigned to receive heart rate (HR) control by continuous infusion of esmolol in combination with the PDE III inhibitor enoximone (Esmolol+Enoximone group) or esmolol alone (Esmolol group; n=14)."( [Continuous beta-block with esmolol in combination with enoximone: influence on cardiac function in high risk patients undergoing vascular surgery].
Boldt, J; Lang, K; Mayer, J; Piper, SN; Röhm, K; Suttner, S, 2008
)
0.85
"We sought to assess the intra- and postoperative haemodynamic effects of continuous perioperative beta-adrenergic blockade combined with phosphodiesterase (PDE) III inhibition and its potential benefits in limiting perioperative myocardial ischaemia in high-risk vascular surgery patients."( Influence of continuous perioperative beta-blockade in combination with phosphodiesterase inhibition on haemodynamics and myocardial ischaemia in high-risk vascular surgery patients.
Boldt, J; Lang, K; Mayer, J; Mengistu, A; Suttner, S, 2009
)
0.35
"Inotropic therapy with the PDE III inhibitor enoximone combined with tight HR control by a continuous infusion of esmolol improved cardiac function and reduced myocardial ischaemia in high-risk vascular surgery patients."( Influence of continuous perioperative beta-blockade in combination with phosphodiesterase inhibition on haemodynamics and myocardial ischaemia in high-risk vascular surgery patients.
Boldt, J; Lang, K; Mayer, J; Mengistu, A; Suttner, S, 2009
)
0.56

Bioavailability

ExcerptReferenceRelevance
" As an important inhibitor of the bioavailability of NO, ADMA is an underlying mechanism of LVH."( Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?
Delgado-Baeza, E; Quintana-Villamandos, B, 2016
)
0.65
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

A multicentre trial was designed to determine the dose-response and side-effects of esmolol when administered as a single iv bolus prior to induction of anaesthesia for controlling the haemodynamic response to tracheal intubation.

ExcerptRelevanceReference
" However 4 patients out of 5 who received the higher dosage of esmolol (3 mg."( [Bolus esmolol prior to tracheal intubation of the elderly patient].
Chabanne, JP; Descraques, C; Mion, G; Ruttimann, M, 1992
)
0.98
" Once the patients had been receiving a maintenance dosage for 30 minutes, Doppler echocardiographic studies were repeated."( Ultra short-acting intravenous beta-adrenergic blockade as add-on therapy in acute unstable angina.
Barth, C; Labovitz, AJ; Ojile, M; Pearson, AC, 1991
)
0.28
" An infusion of esmolol was initiated and dosage was titrated until beta-blockade occurred."( Pharmacokinetics of esmolol in children.
Garner, SS; Gillette, PC; Trippel, DL; Wiest, DB, 1991
)
0.95
" The dosage was increased by 50 to 100 micrograms/kg per minute every 5 to 10 minutes until a reduction of greater than 10% in either heart rate or mean blood pressure was seen."( Cardiovascular and antiarrhythmic effects of esmolol in children.
Gillette, PC; Trippel, DL; Wiest, DB, 1991
)
0.54
"A multicentre trial was designed to determine the dose-response and side-effects of esmolol when administered as a single iv bolus prior to induction of anaesthesia for controlling the haemodynamic response to tracheal intubation."( Bolus administration of esmolol for controlling the haemodynamic response to tracheal intubation: the Canadian Multicentre Trial.
Hill, J; Martineau, RJ; Miller, DR; Wynands, JE, 1991
)
0.81
" However, propranolol significantly shifted the methacholine dose-response curve to the left so that methacholine (0."( Pulmonary reactivity to methacholine during beta-adrenergic blockade: propranolol versus esmolol.
Hirshman, CA; Sauder, RA; Tobias, JD, 1990
)
0.5
" nurse's monitoring specific drug therapy includes familiarity with a drug's action, with its performance in different clinical situations, with proper dosage and observations for adverse effects."( New drug therapies: esmolol HCL, aztreonam and ganciclovir.
Pauley, SY,
)
0.45
" The average esmolol dosage producing a therapeutic response was 97."( Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
Anderson, S; Blanski, L; Byrd, RC; Das, G; Engler, R; Laddu, A; Lee, R; Rajfer, S; Schroeder, J; Steck, JD, 1986
)
0.91
" The results of this study indicate that esmolol is extensively metabolized, and the extent of the metabolism is not dose related in the dosage range used."( Metabolism and urinary excretion of esmolol in humans.
Achari, R; Drissel, D; Hulse, JD; Matier, WL, 1986
)
0.81
" In patients with supraventricular tachyarrhythmias, esmolol produces rapid control of heart rate in an average effective dosage range from 97."( Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
Angaran, DM; Schultz, NJ; Tschida, VH, 1986
)
1.96
" Our dosing schedule began with 30 mg in the first subject and ended with 100 mg and 150 mg in the final four subjects."( Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus.
Hulse, J; Pritchett, EL; Sintetos, AL, 1987
)
0.54
" Controlled drug infusions to maximal dosage (esmolol, 300 micrograms/kg/min, and nitroprusside, 10 micrograms/kg/min) were titrated to achieve at least a 15% reduction in systolic pressure."( Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension.
Bateman, TM; Conklin, C; Czer, LS; Gray, RJ; Matloff, JM, 1987
)
0.89
" Second, if adverse effects are experienced, reducing the dosage or terminating the infusion results in rapid reversal of its pharmacological effects."( Controlled beta-receptor blockade with esmolol and flestolol.
Frishman, WH; Murthy, VS, 1988
)
0.54
" Dosage and administration must be individualized."( Esmolol, the first ultra-short-acting intravenous beta blocker for use in critically ill patients.
Blanski, L; Laddu, A; Lutz, J, 1988
)
1.72
" Therefore, adjustments in dosage of esmolol are not required for patients with Laennec's cirrhosis."( Pharmacokinetics of esmolol in hepatic disease.
Achari, R; Buchi, KN; Drissel, D; Hulse, JD; Rollins, DE; Tolman, KG, 1987
)
0.87
" Heart rate and contractile force dose-response curves to isoproterenol were equally shifted to the right in a dose-dependent, parallel fashion by constant infusion of ASL-8052."( Beta-blocking and hemodynamic effects of ASL-8052.
Gorczynski, RJ; Hwang, TF; Murthy, VS,
)
0.13
" Different dosage schedules have been employed as per the clinical setting and the diagnosis."( Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Appunn, DO; Barbier, GH; Shettigar, UR, 1995
)
0.53
" Clinically, esmolol is used for the following: (i) situations where a brief duration of adrenergic blockade is required, such as tracheal intubation and stressful surgical stimuli; and (ii) critically ill or unstable patients in whom the dosage of esmolol is easily titrated to response and adverse effects are rapidly managed by termination of the infusion."( Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
Wiest, D, 1995
)
2.1
"The purpose of this study was to find a safe dosing regimen for esmolol infusion to rapidly control supraventricular tachyarrhythmia after cardiac surgery in Chinese patients."( A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients.
Chu, SH; Ko, WJ, 1994
)
0.83
"When supraventricular tachyarrhythmia with a rapid ventricular response (> 110/min) was found early after cardiac surgery, esmolol infusion with a different dosing regimen was used to control the tachyarrhythmia."( A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients.
Chu, SH; Ko, WJ, 1994
)
0.8
"With the dosing regimen recommended in western published reports (repeated loading infusion with stepwise increment), acute hypotension with systolic pressure < 80 mm Hg occurred in all six patients after 1 min of loading infusion of esmolol (500 micrograms/kg body weight per min)."( A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients.
Chu, SH; Ko, WJ, 1994
)
0.77
"The dosing regimen for esmolol infusion recommended in western studies is not suitable for Chinese patients."( A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients.
Chu, SH; Ko, WJ, 1994
)
0.9
" It is concluded that esmolol was ineffective at treating preexisting or new-onset myocardial ischemia at this dosage in this clinical setting."( Esmolol and intraoperative myocardial ischemia: a double-blind study.
Bronheim, DS; Lasker, S; Neustein, SM; Reich, DL; Thys, DM, 1994
)
2.05
" There was a big interindividual difference in esmolol dose-response curves in the surviving animals."( Coronary artery operation supported by the Hemopump: an experimental study on pig.
Casimir-Ahn, H; Granfeldt, H; Lönn, U; Peterzén, B, 1994
)
0.55
"To assess the minimal effective dosage of esmolol to prevent hypertension and tachycardia during laryngoscopy and endotracheal intubation in fentanyl-pretreated anesthesia, a double-blinded, randomized study was conducted."( Use of esmolol to prevent hemodynamic changes during intubation in general anesthesia.
Chang, CF; Lin, MS; Wang, SC; Wu, CC, 1994
)
1.01
"To study the neuromuscular interactions between succinylcholine (Sch) and esmolol, we determined the dose-response relationship of Sch and the neuromuscular actions of the 3xED90 dose of Sch, both prior to and following esmolol pretreatment."( Neuromuscular interactions between succinylcholine and esmolol in the rat.
Chang, RY; Chern, SC; Chiang, YY; Liou, MD; Tsai, SK; Tseng, KF, 1994
)
0.77
" In the second protocol, dose-response curves were obtained using isolated (Langendorff) rat and rabbit (n = 6) hearts."( Beyond hyperkalemia: beta-blocker-induced cardiac arrest for normothermic cardiac operations.
Deslauriers, R; Ede, M; Gregorash, L; LeHouerou, D; Lessana, A; Pargaonkar, S; Salerno, TA; Summers, R; Ye, J, 1997
)
0.3
" Two groups of rats were dosed with remifentanil [25 micrograms/kg/min (n = 8)] and remifentanil plus esmolol [25 and 200 mg/kg/min (n = 7)] for 20 min."( Evaluating a possible pharmacokinetic interaction between remifentanil and esmolol in the rat.
Eddington, ND; Haidar, SH; Hoke, JF; Liang, Z; Moreton, JE; Muir, KT, 1997
)
0.74
" Each rat was dosed with REMI (15 micrograms/kg/min), and REMI & ES (15 micrograms/kg/min and 600 micrograms/kg/min) for 21 minutes in a random crossover design."( The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat.
Eddington, ND; Haidar, SH; Hoke, JF; Liang, Z; Moreton, JE; Muir, KT, 1997
)
0.51
"We compared the dose-response relationship and the neuromuscular blocking effects of mivacurium during infusions of esmolol in 40 anaesthetised rabbits."( Neuromuscular interactions between mivacurium and esmolol in rabbits.
Kim, KH; Kim, KS; Shin, WJ; Yoo, HK, 1998
)
0.76
" On final esmolol dose (mean +/- standard deviation dosage 700 +/- 232 microg/kg/min) there was a significant percent decrease in heart rate and systolic and diastolic blood pressures from postoperative values."( Esmolol for the management of pediatric hypertension after cardiac operations.
Garner, SS; Sade, RM; Uber, WE; Wiest, DB, 1998
)
2.15
"The dosage required to control hypertension in patients after repair of aortic coarctation was higher than patients who underwent repair of other congenital heart defects."( Esmolol for the management of pediatric hypertension after cardiac operations.
Garner, SS; Sade, RM; Uber, WE; Wiest, DB, 1998
)
1.74
" Cumulative postoperative dosage of dopamine and dobutamine was 34516+/-40400 microg/kg and 16221+/-26678 microg/kg respectively in CP patients."( Emergency coronary artery surgery after failed PTCA: myocardial protection with continuous coronary perfusion of beta-blocker-enriched blood.
Clemens, RM; de Vivie, ER; Geissler, HJ; Hekmat, K; Kuhn-Régnier, F; Mehlhorn, U, 1998
)
0.3
"Although this is a small study, it suggests that esmolol is more effective in converting patients to normal sinus rhythm than diltiazem during the initial dosing period."( Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery.
Hilleman, DE; Mohiuddin, SM; Mooss, AN; Reyes, AP; Scott, W; Seyedroudbari, A; Sugimoto, JT; Wurdeman, RL, 2000
)
2
", dosing rate or enantiomer-enantiomer interaction) or the patient (e."( Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
Brocks, DR; Mehvar, R,
)
0.13
" The beta-blockers were administered in four dose tiers, with an increase in dosage every 15 min."( Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol.
Baumann, G; Doerffel, W; Felix, SB; Kieback, A; Stangl, K; Stangl, V; Staudt, A; Wernecke, KD, 2001
)
0.52
" Compared to the dosage that was determined before esmolol infusion, the lowest effective dose of adenosine remained the same in 13 patients after the end of esmolol infusion, whereas the dose increased in 5 and decreased in 1 patient."( Interactions of esmolol and adenosine in atrioventricular nodal-dependent supraventricular tachycardia: implication for the cellular mechanisms of adenosine.
Chang, KC; Chen, JY; Chou, HT; Hung, JS; Lin, YC, 2002
)
0.91
" All three beta blockers were equally protective but the intermediate dosage of landiolol preserved LVP during the pre-ischemic period."( Landiolol, esmolol and propranolol protect from ischemia/reperfusion injury in isolated guinea pig hearts.
Fujita, S; Kanaya, N; Kurosawa, S; Nakayama, M; Namiki, A; Niiyama, Y, 2003
)
0.71
" We studied the dose-response and side effects of bolus administration of esmolol hydrochloride in cigarette smokers undergoing elective microlaryngeal surgery, when esmolol was used for reducing the intense hemodynamic response to laryngoscopy and tracheal intubation."( Administration of esmolol in microlaryngeal surgery for blunting the hemodynamic response during laryngoscopy and tracheal intubation in cigarette smokers.
Davilis, DI; Georgiou, LG; Hadzilia, SJ; Louizos, AA; Samanta, EG, 2007
)
0.9
" The repeated times and the total dosage of rocuronium in H group were significantly more than that in E group (P<0."( Hyperthyroidism patients have shorter onset and duration time of rocuronium than euthyroidism patients.
Feng, SW; Ge, YL; He, LL; Song, XJ; Wang, YG; Yang, JJ, 2007
)
0.34
"The markedly disparate action of drugs blocking beta-receptors at low dosage seems to be related to the heterogeneous extent, and time course, of systolic loading of the myocytes."( Beta-blockade at low doses restoring the physiological balance in myocytic antagonism.
Anderson, RH; Batista, RV; Cryer, CW; Lunkenheimer, PP; Niederer, P; Redmann, K; Stanton, JJ, 2007
)
0.34
" The dose-response curves of Raw and Cdyn to acetylcholine were significantly elevated and declined in the ovalbumin-sensitized model compared with those in the control group."( Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity.
Iwasaki, S; Jeong, SW; Namiki, A; Satoh, J; Yamakage, M,
)
0.38
"Esmolol improves significantly the outcome of cardiopulmonary resuscitation and the average time of restoration of circulation, while in the proposed dosage does not alter the CPP at the beginning of CPR."( Selective beta blockade improves the outcome of cardiopulmonary resuscitation in a swine model of cardiac arrest.
Condilis, N; Demestiha, T; Papadimitriou, D; Papadimitriou, L; Theochari, E; Tsiftsi, K; Tsirikos-Karapanos, N; Xanthos, T,
)
1.57
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" This dose was obtained from an ESM dose-response curve which induces at least 80% arrest in rats."( Protective effects of a magnesium magnetic isotope (Mg25)-exchanging nanoparticle (25MgPMC16 ) on mitochondrial functional disorders in esmolol-induced cardiac arrest in rats.
Adeli, S; Bidgoli, SA; Ghasemzadeh, P; Korani, M; Niknahad, H; Rezayat, SM; Sarkar, S; Zarrindast, MR, 2012
)
0.58
" Dosing requirements to achieve targeted blood pressure in post-coarctectomy patients were substantially higher (mean 700 μg/kg/min) than that used in adults."( Clinical pharmacokinetics and therapeutic efficacy of esmolol.
Haney, JS; Wiest, DB, 2012
)
0.63
"Although selective beta-1 adrenoceptor antagonists are known to provide neuroprotective effects after brain ischemia, dose-response relationships of their neuroprotective effects have not been examined."( Neuroprotective effects of selective β-1 adrenoceptor antagonists, landiolol and esmolol, on transient forebrain ischemia in rats; a dose-response study.
Goyagi, T; Horiguchi, T; Masaki, Y; Nishikawa, T; Tobe, Y, 2012
)
0.61
" Cumulative postoperative dosage of dopamine in the esmolol group (100."( Protective effect of esmolol on myocardial ischemic injury during open heart surgery in children.
Gui, P; Wu, J; Wu, Q; Yao, S, 2013
)
0.96
" We assessed the safety and tolerability of acute dosing with esmolol and propranolol in patients with asthma."( Effects of intravenous and oral β-blockade in persistent asthmatics controlled on inhaled corticosteroids.
Anderson, WJ; Lipworth, BJ; Short, PM; Williamson, PA, 2014
)
0.64
" Tiotropium prevented propranolol induced bronchoconstriction after acute dosing during up-titration to 80 mg with no adverse impact on asthma control."( Effects of intravenous and oral β-blockade in persistent asthmatics controlled on inhaled corticosteroids.
Anderson, WJ; Lipworth, BJ; Short, PM; Williamson, PA, 2014
)
0.4
" Dose-response curves for acetylcholine (ACh) and sodium nitroprusside were constructed."( Short-term esmolol improves coronary artery remodeling in spontaneously hypertensive rats through increased nitric oxide bioavailability and superoxide dismutase activity.
Arnalich-Montiel, A; Condezo-Hoyos, L; Delgado-Baeza, E; Delgado-Martos, MJ; González, MC; Martos-Rodríguez, A; Quintana-Villamandos, B; Rodríguez-Rodríguez, P, 2014
)
0.79
" In healthy volunteers we found more pronounced myocardial shortening at low compared with clinical dosage of beta-blockers."( Effects of incremental beta-blocker dosing on myocardial mechanics of the human left ventricle: MRI 3D-tagging insight into pharmacodynamics supports theory of inner antagonism.
Anderson, RH; Berger, F; Khasheei, A; Kühne, T; Kutty, S; Li, T; Lunkenheimer, PP; Peters, B; Schmitt, B; Schmitt, KR, 2015
)
0.42
" Heart rate(HR) and mean arterial pressure(MAP) during controlled hypotension (the difference between the highest and lowest values and the percentage of basic values), intraoperative blood loss, allogeneic blood transfusion, operation time and dosage of propofol and remifentanil were compared between the two groups."( [Comparison of the effects of dexmedetomidine and esmolol on controlled hypotension in patients with orthognathic surgery].
Jian, C; Jiang, J; Lin, Y, 2021
)
0.87
"Compared with esmolol, the effect of Dex on controlled hypotension during orthognathic surgery is more stable and the dosage of propofol and remifentanil is decreased."( [Comparison of the effects of dexmedetomidine and esmolol on controlled hypotension in patients with orthognathic surgery].
Jian, C; Jiang, J; Lin, Y, 2021
)
1.24
" There was also a significant increase in intraoperative esmolol dosage in the CFNB group (65."( Combined femoral artery block and femoral nerve block reduces thigh tourniquet-induced hypertension.
Gao, F; Li, W; Li, Y; Wang, Q; Wang, X; Xu, F; Yin, C; Yu, J; Zhu, L, 2023
)
1.16
"The present study demonstrated that modified femoral nerve block reduced intraoperative esmolol dosage and the incidence of TH."( Combined femoral artery block and femoral nerve block reduces thigh tourniquet-induced hypertension.
Gao, F; Li, W; Li, Y; Wang, Q; Wang, X; Xu, F; Yin, C; Yu, J; Zhu, L, 2023
)
1.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (5)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
ethanolamines
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Esmolol Action Pathway478

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.19700.00021.46819.0000AID625204
Beta-1 adrenergic receptorHomo sapiens (human)Ki0.11370.00011.33919.9840AID625204
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-1 adrenergic receptor Cavia porcellus (domestic guinea pig)Kd0.05000.00000.53588.3176AID39950; AID42217; AID79651; AID79652
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1668041Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID16680In vitro hydrolytic rate constant determined in human blood1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Soft drugs. 7. Soft beta-blockers for systemic and ophthalmic use.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID25657Half life period determined in human blood1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Soft drugs. 7. Soft beta-blockers for systemic and ophthalmic use.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID42217Activity at beta-1 adrenergic receptor1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Computer-aided mapping of the beta-adrenoceptor. 1. Explanation for effect of para substitution on blocking activity at the beta-1-adrenoceptor.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1668035Antiproliferative activity against human A375 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID79651Ability to block Beta-1 adrenergic receptor in guinea pig right atria preparation at a duration of 3h1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1668034Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID228305Cardioselectivity expressed as antilog of pA2 (atria)-pA2 (trachea).1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID40877Ability to block Beta-2 adrenergic receptor in guinea pig trachea preparation1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.
AID1668042Antiproliferative activity against human A375 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID39950Ability to block Beta-1 adrenergic receptor in guinea pig right atria preparation1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1668032Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition at 100 uM incubated for 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID79652Ability to block Beta-1 adrenergic receptor in guinea pig right atria preparation at a duration of 40 min1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.
AID1668033Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (949)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990123 (12.96)18.7374
1990's274 (28.87)18.2507
2000's263 (27.71)29.6817
2010's233 (24.55)24.3611
2020's56 (5.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.91 (24.57)
Research Supply Index7.20 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index135.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials309 (30.21%)5.53%
Reviews90 (8.80%)6.00%
Case Studies132 (12.90%)4.05%
Observational3 (0.29%)0.25%
Other489 (47.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (85)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Anti-inflammatory and Cardiac Effects of Esmolol in Septic Shock. ESMOSEPSIS Study [NCT02068287]Phase 225 participants (Anticipated)Interventional2013-12-31Recruiting
Adrenergic Blockade After Subarachnoid Hemorrhage [NCT01232400]0 participants (Actual)Interventional2014-07-31Withdrawn(stopped due to Funding withdrawn. Design not feasible.)
Strict Heart Rate Control With Esmolol in Septic Shock: a Randomized, Controlled, Clinical Pilot Study [NCT01231698]Phase 2154 participants (Actual)Interventional2010-12-31Completed
The Effect of Dexmedetomidine and Esmolol on Early Post Operative Cognitive Dysfunction After Middle Ear Surgery Under Hypotensive Technique :Comparative , Randomized Double Blinded Study [NCT03892512]Phase 1/Phase 258 participants (Anticipated)Interventional2019-04-30Recruiting
Nanjing First Hospital, Nanjing Medical University [NCT01171911]Phase 4200 participants (Anticipated)Interventional2010-10-31Not yet recruiting
A Prospective, Randomized, Double Blinded, Crossover, Two-treatment, Two-sequence, Short Term Pharmacokinetic, Pharmacodynamic and Tolerability, Single Centre Study to Compare AOP200704 vs. Esmolol in Healthy Subjects. [NCT01313143]Phase 216 participants (Actual)Interventional2011-03-31Completed
Effect of Continuous Infusion of Esmolol on Perioperative Stress Reaction in Patients Undergoing Airway Intervention [NCT05694585]Phase 446 participants (Anticipated)Interventional2023-02-01Not yet recruiting
Controlling Hyperadrenergic Activity in Neurologic Injury [NCT01343329]Phase 1/Phase 20 participants (Actual)Interventional2011-07-31Withdrawn(stopped due to Unable to enroll subjects that fit study criteria.)
The Effects of Lidocaine and Esmolol on Attenuation of Hemodynamic Response to Orotracheal Intubation: A Double-blind, Randomized, Clinical Trial [NCT03612492]Phase 480 participants (Anticipated)Interventional2018-07-01Recruiting
Usefulness of Pupillary Reflex on Remifentanil and Morphine Consumption During Laparoscopic Surgery. A Bicentric, Prospective, Randomized, Controlled Trial. [NCT02116868]100 participants (Actual)Interventional2014-03-31Completed
Effects of Intraoperative Esmolol on Post-mastectomy Pain Syndrome: a Cross-sectional Study [NCT03965442]66 participants (Anticipated)Observational2019-01-01Recruiting
Analgesic Effect of Intraoperative Esmolol in Mastectomies: Single Center, Prospective, Double-blind, Randomized and Placebo Controlled Study [NCT02466542]Phase 460 participants (Anticipated)Interventional2015-06-30Completed
Efficacy of Esmolol Versus Magnesium Sulphate on Quality of Recovery in Patients Undergoing Laparoscopic Cholecystectomy: Randomized Controlled Study [NCT05850832]Phase 2/Phase 360 participants (Actual)Interventional2022-10-05Completed
Myocardial Protection With Esmolol in Patients With Hypertrophic Obstructive Cardiomyopathy Undergoing Surgery Under Cardiopulmonary Bypass [NCT05073094]Phase 480 participants (Anticipated)Interventional2021-10-06Recruiting
Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction [NCT02098629]Phase 1/Phase 20 participants (Actual)Interventional2015-05-31Withdrawn(stopped due to Difficulty in enrollment)
Heart Rate Reduction With Esmolol is Associated With Improved Arterial Elastance in Patients With Septic Shock. A Prospective Observational Study [NCT02188888]45 participants (Actual)Observational2013-12-31Completed
Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients:A Multicenter, Prospective, Double-blind, Randomized Controlled Study [NCT05635877]Phase 42,000 participants (Anticipated)Interventional2023-02-07Recruiting
An Interventional, Placebo-Controlled, Randomized, Double-blinded Dose Comparison, Phase I/II Study to Determine the Safety and Efficacy of a New Gel Formulation of Esmolol Hydrochloride (Galnobax®) for the Treatment of Diabetic Foot Ulcer (DFU) [NCT01113515]Phase 1/Phase 250 participants (Anticipated)Interventional2014-02-28Active, not recruiting
Fast-track Laparoscopic Surgery. The Effect of Anesthetic Technique [NCT01275911]40 participants (Actual)Interventional2009-01-31Completed
A Phase 1, Open-label Study to Compare the Pharmacokinetics and Pharmacodynamics of Warfarin and Esmolol in the Absence and Presence of MEDI0382 in Healthy Subjects [NCT03347968]Phase 122 participants (Actual)Interventional2017-11-27Completed
Lecturer of Anesthesia [NCT04086940]Phase 460 participants (Anticipated)Interventional2019-11-30Not yet recruiting
The Effects of Esmolol on the Hemodynamic Response to Orotracheal Extubation: a Prospective, Randomized, Double-blind and Placebo-controlled Trial [NCT04264286]Phase 480 participants (Anticipated)Interventional2019-07-01Recruiting
An Open-Label, Sequential-Group, Dose-Escalation Study To Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Tecadenoson Alone and in Combination With a Beta-Blocker in Adults With Rapid Atrial Fibrillation (CVT 4129) [NCT00713401]Phase 221 participants (Actual)Interventional2008-02-29Completed
The Effects of the Drugs Used in Hypotensive Anaesthesia on Cochlea [NCT02062333]Phase 447 participants (Actual)Interventional2014-01-31Completed
Esmolol to Control Adrenergic Storm in Septic Shock- ROLL-IN 2 [NCT03208257]Phase 210 participants (Anticipated)Interventional2017-08-07Recruiting
Impact of Early CRRT Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality: A Randomized Controlled Trial [NCT03549923]Phase 4550 participants (Anticipated)Interventional2018-12-18Recruiting
A Randomized, Participant-blinded Five-arm Crossover Study With Blinded Outcome Assessment Investigating Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition. [NCT03533179]Phase 410 participants (Actual)Interventional2018-06-01Completed
The Effect of Esmolol on Tissue Perfusion and Clinical Prognosis of Patients With Severe Sepsis: a Prospective Cohort Study . [NCT02794025]151 participants (Actual)Interventional2010-01-31Completed
Esmolol in Cardiac Surgery. A Randomized Controlled Trial With Clinical [NCT00959569]Phase 4200 participants (Actual)Interventional2009-08-31Completed
A Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study to Evaluate the Safety and Efficacy of a Gel Formulation of Esmolol Hydrochloride (Galnobax®) in Treating Diabetic Foot Ulcers [NCT03998436]Phase 3176 participants (Actual)Interventional2018-12-26Completed
Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures [NCT02563288]Phase 360 participants (Anticipated)Interventional2016-08-31Recruiting
The Effects of ß1-receptor Blockade and α1-adrenergic Agonist on the Kinetics of Lactated Ringer's Solution During Surgery [NCT01431612]Phase 1/Phase 260 participants (Actual)Interventional2008-11-30Completed
Manipulation of Arterial Pressure Early in Non Thrombolysed Acute Ischemic Stroke: Effects on Death and Neurological Disability [NCT00848770]240 participants (Anticipated)Interventional2008-01-31Recruiting
The Effect of Esmolol Versus Dexmedetomidine on Postoperative Pain Control in Endoscopic Sinus Surgery: A Randomized Trial [NCT05703048]70 participants (Anticipated)Interventional2022-12-30Recruiting
Safety and Efficacy of Esmolol for the Treatment of Peri-operative Tachycardia in Patients at Risk for Post Operative Adverse Ischemic Outcomes [NCT01208402]Phase 376 participants (Actual)Interventional2010-09-30Terminated(stopped due to Baxter has terminated the study for inadequate enrollment rate accrual.)
A Study in Healthy Subjects to Evaluate Genetic Determinants of the Variability in Hemodynamic Response to Esmolol [NCT01388036]100 participants (Anticipated)Interventional2011-07-31Recruiting
Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol: A Study Comparing the Post Op Continuation of the Preoperative Oral Dose Beta Blockers to Intravenous Esmolol Titrated to a Target Heart Rate (HR) [NCT01404767]Phase 420 participants (Actual)Interventional2011-04-30Terminated(stopped due to Enrollment slow over 2 years a change in the population less on metoprolol than initially anticipated)
Closed-loop Delivery of Propofol and Remifentanil: Sparing Effect of Esmolol [NCT00922467]Phase 315 participants (Actual)Interventional2009-06-30Terminated(stopped due to lack of effectiveness)
Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients [NCT02842983]Phase 2/Phase 336 participants (Anticipated)Interventional2014-12-31Recruiting
The Effects of Preintubation Esmolol and and Dexmedotimidine on Ischmeia Modified Albumin Levels [NCT02844894]Phase 460 participants (Anticipated)Interventional2016-06-30Recruiting
Effect of a Continuous Infusion of Esmolol on Stroke Volume in Patients With Hyperdynamic Vasoplegic Septic Shock: a Multicentre, Randomized, Double-blind Trial [NCT02609152]Phase 30 participants (Actual)Interventional2016-07-31Withdrawn(stopped due to logistical difficulties)
Effect of Dexmedetomidine vs Esmolol or Placebo on Cerebral Hemodynamics in Septic Shock: A Randomized Clinical Trial. [NCT06169475]14 participants (Actual)Interventional2020-11-01Completed
Esmolol Pretreatment on Pain During Injection of Propofol [NCT01885364]120 participants (Actual)Interventional2015-06-30Completed
The Effect of Esmolol on Patients With Sepsis [NCT04537767]120 participants (Anticipated)Interventional2020-10-01Not yet recruiting
Effects of Esmolol on Oxygenation Index by Controlling Heart Rate in Patients With Acute Respiratory Distress Syndrome [NCT06013319]Phase 3178 participants (Anticipated)Interventional2023-11-01Not yet recruiting
Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion [NCT04181606]Early Phase 10 participants (Actual)Interventional2021-12-31Withdrawn(stopped due to Organizational Changes and Covid-related delays)
Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study [NCT04306913]80 participants (Anticipated)Interventional2020-04-30Not yet recruiting
An International Randomised Controlled Trial to Establish the Effects of Low-dose rtPA and the Effects of Early Intensive Blood Pressure Lowering in Patients With Acute Ischaemic Stroke [NCT01422616]Phase 34,587 participants (Actual)Interventional2012-03-31Completed
The Influence of Continuous Perioperative Beta-Blocker Therapy in Combination With Phosphodiesterase Inhibition on Cardiac Neurohormonal Activation and Myocardial Ischaemia in High-Risk Vascular Surgery Patients [NCT00348101]Phase 375 participants (Actual)Interventional2006-06-30Completed
Comparison of Calcium-channel Blockers and Beta Blockers in Tourniquet-induced Hypertension During Intravenous Regional Anesthesia [NCT02319161]50 participants (Actual)Observational2014-06-30Completed
Effect of Controlled Hypotension on Cerebral Oxygen Saturation in Patients Undergoing Functional Endoscopic Sinus Surgery: a Prospective Randomized Single Blind Clinical Trial [NCT02967029]Phase 4150 participants (Actual)Interventional2016-11-01Completed
"Effects of Beta-Blockade on Cardiovascular Morbidity and Mortality in Elderly Trauma Patients: A Prospective Randomized Clinical Trial" [NCT00302692]Phase 2148 participants (Anticipated)Interventional2005-12-31Recruiting
Intraoperative Lidocaine Versus Esmolol Infusion for Optimizing Surgical Field Visibility During Lumbar Discectomy [NCT04260685]Phase 270 participants (Actual)Interventional2020-02-04Completed
The Impact on Postoperative Pain of Substituting Opioids by Beta Blockers for Peroperative Hemodynamic Control in Patients Undergoing Mastectomy [NCT01544959]84 participants (Anticipated)Interventional2010-01-31Completed
A Randomised Trial to Establish the Effects of Early Intensive Blood Pressure Lowering on Death and Disability in Patients With Stroke Due to Acute Intracerebral Haemorrhage [NCT00226096]404 participants (Actual)Interventional2005-11-30Completed
Esmolol Reduces Anesthetic Requirements Thereby Facilitating Early Extubation; a Prospective Controlled Study in Patients Undergoing Intracranial Surgery [NCT02455440]Phase 350 participants (Actual)Interventional2014-03-31Completed
Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock [NCT02120404]Phase 245 participants (Anticipated)Interventional2015-04-30Active, not recruiting
Nicardipine Versus Esmolol for Management of Emergence Hypertension After Craniotomy [NCT01951950]Phase 140 participants (Actual)Interventional2013-09-30Completed
A Comparison of the Perioperative Hemodynamic Effects of Remifentanil and Esmolol: a Double Blind Randomized Controlled Study [NCT01628562]Phase 440 participants (Actual)Interventional2012-06-30Completed
A Single Centre Prospective, Randomized, Double Blind, Crossover, Three-treatment Periods PK, PD, Safety and Tolerability Study to Compare Bolus Administration of AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers After a Pilot Phase of AOP LDLA202 [NCT01652898]Phase 112 participants (Actual)Interventional2012-07-31Completed
The Effect of Intraoperative Esmolol Administration on Postoperative Recovery and Chronic Pain [NCT05567822]70 participants (Anticipated)Interventional2022-10-01Recruiting
Prospective, Multicenter and Open Study to Evaluate the Efficacy of Esmolol in the Early Identification of Cardiovascular Disorders Induced by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments [NCT05769868]Phase 31,000 participants (Anticipated)Interventional2023-04-18Recruiting
A Single Centre Prospective, Randomized, Double Blind, Crossover, Pharmacokinetic, Safety and Tolerability Study to Compare Long-term Infusion Administration of LDLL600 Against Esmolol in Healthy Volunteers. [NCT01741519]Phase 114 participants (Actual)Interventional2012-12-31Completed
A Randomized Comparison of Esmolol and Remifentanil on Intraoperative Bleeding and Surgical Field Conditionsin Nasal Surgery [NCT01752959]Phase 460 participants (Anticipated)Interventional2012-07-31Recruiting
The Effect of Esmolol on Pain Due to Rocuronium Injection Pain [NCT01824758]Phase 490 participants (Actual)Interventional2013-03-31Completed
Effects of Heart Control at Different Stages on Hemodynamics Parameters and Clinical Prognosis in Patients of Septic Shock With Tachycardia [NCT05389176]96 participants (Anticipated)Interventional2022-07-01Not yet recruiting
Effect of Lidocaine and Esmolol Alone or in Combination to Improve the Quality of Recovery, Maintaining Hemodynamic Stability During Abdominal Surgery [NCT01114997]Phase 432 participants (Actual)Interventional2010-04-30Terminated(stopped due to The early report didn't show any benefit.)
Randomized, Double-Blinded, Active-Controlled Study to Evaluate the Intraoperative Use of Labetalol vs. Esmolol for Maintaining Hemodynamic Stability During Laparoscopic Surgery: Effect on Recovery and Postoperative Pain [NCT01114971]Phase 475 participants (Actual)Interventional2009-09-03Completed
Comparison of Hemodynamic Changes With Morphine Versus Esmolol as an Adjuvant Agent During Induction of Anaesthesia [NCT06065956]Phase 1/Phase 2110 participants (Actual)Interventional2022-08-28Completed
Dose Esmolol Infusion Have an Adjuvant Effect to Transversus Abdominis Plane Block for Pain Control in Laparoscopic Cholecystectomy: A Randomized Controlled Double-blind Trial. [NCT04752111]Phase 460 participants (Actual)Interventional2021-01-19Completed
Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation After Non-cardiac Non-thoracic Surgery [NCT05950971]1 participants (Actual)Interventional2021-07-01Terminated(stopped due to Study enrollment too slow, 1 over 6 months)
Changes in Cerebral Oxygenation and Cognitive Functions During Controlled Hypotension [NCT04948957]40 participants (Actual)Observational2014-03-01Completed
A Randomized, Exploratory, Open-label, Phase IV, Blinded Endpoint, Multicenter and Prospective Study to Evaluate the Effect of the Addition of Esmolol on the Current Therapeutic Regimen Used for the Treatment of Hemorrhagic Stroke [NCT03743103]Phase 420 participants (Actual)Interventional2019-04-18Terminated(stopped due to Low enrollement)
Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass(CPB) in Cardiac Surgery: a Randomized, Controlled Trial [NCT01212874]70 participants (Actual)Interventional2010-12-31Completed
Esmolol to Treat the Hemodynamic Effects of Septic Shock [NCT02369900]Phase 240 participants (Actual)Interventional2015-03-31Terminated(stopped due to Funding expired, low enrollments)
Esmolol to Control Adrenergic Storm in Septic Shock - Roll-in [NCT02841241]Phase 27 participants (Actual)Interventional2016-04-30Completed
Blood Loss and Visibility With Esmolol vs. Labetalol in Endoscopic Sinus Surgery: A Randomized Trial [NCT03661346]Phase 228 participants (Actual)Interventional2017-03-01Completed
Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy: a Randomized Clinical Trial [NCT02327923]Phase 490 participants (Actual)Interventional2015-01-31Completed
An International Randomised Controlled Trial to Establish the Effects of Early Intensive Blood Pressure Lowering in Patients With Intracerebral Haemorrhage. [NCT00716079]2,839 participants (Actual)Interventional2008-09-30Completed
Esmolol Infusion for Maintaining Hemodynamic Stability During Single or Double Level Lumbar Laminectomy: Effect on Quality of Recovery. [NCT01179113]Phase 433 participants (Actual)Interventional2011-06-30Terminated(stopped due to The preliminary result didn't show any benefit.)
A Comparison of Lidocaine, Esmolol, and Placebo Without Use of a Tourniquet for Relieving Pain From Intravenous Administration of Propofol [NCT04356352]Phase 2/Phase 327 participants (Actual)Interventional2020-09-09Terminated(stopped due to feasibility of enrollment)
The Effect of Intraoperative Labetalol on Time to Discharge and Hemodynamic Stability in Laparoscopic Cholecystectomy [NCT02997800]Phase 2172 participants (Actual)Interventional2012-11-30Completed
A Comparison of the Effect of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement [NCT00756236]60 participants (Actual)Interventional2008-10-31Completed
The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery [NCT01782898]70 participants (Actual)Interventional2013-01-31Completed
Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial Pilot Study (AIRCRAFT) [NCT04234477]Phase 40 participants (Actual)Interventional2021-12-31Withdrawn(stopped due to The study was not IRB approved and there were anticipated challenges in recruiting participants.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00716079 (2) [back to overview]A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS)
NCT00716079 (2) [back to overview]Death at 90 Days
NCT00756236 (1) [back to overview]Area Under the Curve of etSEV Over the First Hour
NCT01114971 (6) [back to overview]Low Appetite
NCT01114971 (6) [back to overview]Number of Participant With Opioid Consumption
NCT01114971 (6) [back to overview]Patient Satisfaction Using a Verbal Rating Scale From 0 to 10
NCT01114971 (6) [back to overview]Postoperative Nausea and Vomiting
NCT01114971 (6) [back to overview]Postoperative Pain
NCT01114971 (6) [back to overview]Return to Feeling Normal
NCT01114997 (7) [back to overview]Post Operative Pain
NCT01114997 (7) [back to overview]Number of Participants With Post Operative Pain One Month After Surgery
NCT01114997 (7) [back to overview]Number of Participants With Postoperative Nausea One Day After Surgery
NCT01114997 (7) [back to overview]Opioid Consumption Obtained From the Recorded Data
NCT01114997 (7) [back to overview]Patient Satisfaction
NCT01114997 (7) [back to overview]Post-anesthesia Care Unit (PACU) Stay
NCT01114997 (7) [back to overview]Return to Normal Activities of Daily Living Using Follow up Questionnaires
NCT01179113 (3) [back to overview]Postoperative Nausea and Vomiting
NCT01179113 (3) [back to overview]Post-operative Pain Using Verbal Rating Scale (VRS)
NCT01179113 (3) [back to overview]Opioid Consumption in PACU Obtained From the Recorded Data
NCT01208402 (6) [back to overview]Percentage of Intraoperative Case Time With Heart Rate (HR) <60 or >80 Bpm
NCT01208402 (6) [back to overview]Percentage of Intraoperative Case Time With Systolic Blood Pressure <95 mmHg
NCT01208402 (6) [back to overview]Percentage of Postoperative First Three Hours With Heart Rate (HR) <60 or >80 Bpm
NCT01208402 (6) [back to overview]Percentage of Postoperative First Three Hours With Systolic Blood Pressure <95 mmHg
NCT01208402 (6) [back to overview]Percentage of Postoperative Hours 4 to 12 With Heart Rate (HR) <60 or >80 Bpm.
NCT01208402 (6) [back to overview]Percentage of Postoperative Hours 4 to 12 With Systolic Blood Pressure <95 mmHg
NCT01212874 (2) [back to overview]Diastolic Blood Pressure Excursions Beyond Predetermined Lower Limits, Normalized Per Hour
NCT01212874 (2) [back to overview]Title: Systolic Hypertension
NCT01782898 (3) [back to overview]Post Operative Pain Reported by the Subject.
NCT01782898 (3) [back to overview]Postoperative Opioid Consumption
NCT01782898 (3) [back to overview]Qor-40 at 24 Hours Postoperative
NCT01951950 (1) [back to overview]Failure of Drug to Control Systolic Blood Pressure (SBP) < 140 mmHg
NCT02369900 (11) [back to overview]Lactate
NCT02369900 (11) [back to overview]Overall Need for Vasopressor Support
NCT02369900 (11) [back to overview]Oxygen Consumption (VO2)
NCT02369900 (11) [back to overview]TNF-alpha
NCT02369900 (11) [back to overview]Heart Rates Between Groups
NCT02369900 (11) [back to overview]C-reactive Protein
NCT02369900 (11) [back to overview]Interleukin-10
NCT02369900 (11) [back to overview]Time to Shock Reversal
NCT02369900 (11) [back to overview]Need for Vasopressor Support, Measured as Mean Norepinephrine Equivalent Dose (mcg/kg/Min), at 6hr Time Point
NCT02369900 (11) [back to overview]Interleukin-4
NCT02369900 (11) [back to overview]Interleukin-6
NCT02841241 (8) [back to overview]All-cause Mortality
NCT02841241 (8) [back to overview]Development of Heart Block
NCT02841241 (8) [back to overview]Left Ventricular Global Longitudinal Strain at 24 Hours
NCT02841241 (8) [back to overview]Number of Participants With Intolerance to Esmolol Infusion at Any Given Rate
NCT02841241 (8) [back to overview]Organ-failure-free Days
NCT02841241 (8) [back to overview]Peak Serum High-sensitivity Troponin
NCT02841241 (8) [back to overview]Percentage Hourly Checks During Which Protocol Compliance Was Observed
NCT02841241 (8) [back to overview]Proportion of Compliance With Final Safety Check
NCT03661346 (5) [back to overview]Average Heart Rate
NCT03661346 (5) [back to overview]Average Mean Arterial Blood Pressure
NCT03661346 (5) [back to overview]Intra-operative Surgical Visibility - Boezaart Scale
NCT03661346 (5) [back to overview]Intra-operative Surgical Visibility - Wormald Scale
NCT03661346 (5) [back to overview]Rate of Blood Loss
NCT03998436 (3) [back to overview]Proportion of Subjects Achieving Target Ulcer Closure Within 12-week Treatment Phase, as Assessed by Blinded Investigator
NCT03998436 (3) [back to overview]Proportion of Subjects With Treatment Emergent Adverse Events (TEAEs)
NCT03998436 (3) [back to overview]Proportion of Subjects Achieving Target Ulcer Closure Till End of Study, as Assessed by the Blinded Investigator.

A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS)

(NCT00716079)
Timeframe: 90 days

Interventionparticipants (Number)
Intensive Blood-Pressure Lowering719
Guideline-Recommended Blood-Pressure Lowering785

[back to top]

Death at 90 Days

(NCT00716079)
Timeframe: 90 days

Interventionparticipants (Number)
Intensive Blood-Pressure Lowering166
Guideline-Recommended Blood-Pressure Lowering170

[back to top]

Area Under the Curve of etSEV Over the First Hour

We will measure the amount of Sevoflurane used to achieve the same level Bispectral Index. Each patient will have their percentage of sevoflurane in expired breath measured every 5 minutes for 2 hours, resulting in 24 data points per person. The primary endpoint will be area under the curve (AUC) for each subject for the first hour. (NCT00756236)
Timeframe: Every 5 minutes for 2 hours

Interventionpercent*hour (Mean)
M-Group1.77
E-Group1.46
P-Group1.73

[back to top]

Low Appetite

Participant who experienced low appetite (follow up questionnaire) (NCT01114971)
Timeframe: 1 month

Interventionparticipants (Number)
Fentanyl15
Labetalol7
Esmolol9

[back to top]

Number of Participant With Opioid Consumption

n=Post discharge use of opioid consumption NUMBER OF PARTICIPANTS WHO TOOK PAIN KILLER PILLS (NCT01114971)
Timeframe: 1 month

Interventionparticipants (Number)
Fentanyl15
Labetalol14
Esmolol13

[back to top]

Patient Satisfaction Using a Verbal Rating Scale From 0 to 10

Patient satisfaction using a verbal rating scale from 0 to 10 Where a VRS is a subjective measure in which individuals verbally rated their level of satisfaction on an eleven-point numerical scale. The scale is composed of 0 (excellent satisfaction) to 10 (NCT01114971)
Timeframe: 1 month

Interventionscore on a scale (0-10) (Mean)
Fentanyl9.1
Labetalol9
Esmolol8

[back to top]

Postoperative Nausea and Vomiting

Nausea and vomiting will be measured at PACU (NCT01114971)
Timeframe: 1 day

Interventionparticipants (Number)
Fentanyl9
Labetalol4
Esmolol7

[back to top]

Postoperative Pain

Postoperative pain will be measured at PACU using a Verbal Rating Scale (VRS) from 0 to 10 VRS is a subjective measure in which individuals verbally rate their pain on an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain) (NCT01114971)
Timeframe: one day

InterventionScore on scale 0-10 (Mean)
Fentanyl3.2
Labetalol3
Esmolol3.9

[back to top]

Return to Feeling Normal

Days to report to return to feeling normal, using follow up questionnaires (NCT01114971)
Timeframe: 1 month

InterventionDays (Mean)
Fentanyl11
Labetalol10
Esmolol12

[back to top]

Post Operative Pain

Outcome had a duration of one day at post-anesthesia care unit (PACU) Postoperative pain measured using a Verbal Rating Scale (VRS) Postoperative pain VRS scores: 0 = none pain to 10 = intolerable pain. (NCT01114997)
Timeframe: 1 day

InterventionScore on a scale (Mean)
Lidocaine4
Esmolol2
Lidocaine + Esmolol (Combo)4

[back to top]

Number of Participants With Post Operative Pain One Month After Surgery

"Highest Post Operative pain one month after surgery, using a verbal rating score from 0 (no pain) to 10 (highest level of pain).~Patient received a post-operative follow-up call one month after surgery." (NCT01114997)
Timeframe: 1 month

Interventionparticipants (Number)
Lidocaine10
Esmolol8
Lidocaine + Esmolol (Combo)10

[back to top]

Number of Participants With Postoperative Nausea One Day After Surgery

Postoperative nausea using a Verbal Rating Scale Outcomes measured at the first day after surgery (NCT01114997)
Timeframe: 1day

Interventionparticipants (Number)
Lidocaine3
Esmolol2
Lidocaine + Esmolol (Combo)3

[back to top]

Opioid Consumption Obtained From the Recorded Data

Postoperative use of opioid consumption inside hospital (recorded by study staff and data obtained from patient charts) (NCT01114997)
Timeframe: 1 day

Interventionmg (Mean)
Lidocaine1.5
Esmolol1
Lidocaine + Esmolol (Combo)1.5

[back to top]

Patient Satisfaction

Patient satisfaction using a verbal rating scale from 0 to 10 0= Not satisfied 10= Excellent (NCT01114997)
Timeframe: 1 month

InterventionScore on a scale (Mean)
Lidocaine9.4
Esmolol9.2
Lidocaine + Esmolol (Combo)8.3

[back to top]

Post-anesthesia Care Unit (PACU) Stay

(NCT01114997)
Timeframe: 1 day

InterventionMinutes (Mean)
Lidocaine236
Esmolol116
Lidocaine + Esmolol (Combo)214

[back to top]

Return to Normal Activities of Daily Living Using Follow up Questionnaires

Description: return to normal activities of daily living(including dietary intake, bowel and bladder function, physical activities) (NCT01114997)
Timeframe: 1 month

Interventionparticipants (Number)
Lidocaine10
Esmolol8
Lidocaine + Esmolol (Combo)8

[back to top]

Postoperative Nausea and Vomiting

Number of participants that experienced Postoperative nausea and vomiting using at PACU (NCT01179113)
Timeframe: 1 day

Interventionparticipants (Number)
Placebo2
Esmolol0

[back to top]

Post-operative Pain Using Verbal Rating Scale (VRS)

"Verbal Rating Scale goes from 0 to 10, where:~0 indicates= No pain and 10 indicates= The worst possible pain~The information was be recorded by study staff and data obtained from patient and patient charts from post-anesthesia care unit (PACU) stay" (NCT01179113)
Timeframe: 1 day

InterventionScores on a scale (Mean)
Placebo4
Esmolol5

[back to top]

Opioid Consumption in PACU Obtained From the Recorded Data

Postoperative use of opioid (Hydromorphone) consumption inside hospital at PACU (recorded by study staff and data obtained from patient charts). (NCT01179113)
Timeframe: 1 day

Interventionmg (Mean)
Placebo1.5
Esmolol2

[back to top]

Percentage of Intraoperative Case Time With Heart Rate (HR) <60 or >80 Bpm

Duration of intraoperative excursion (ie, time spent) outside Target HR range defined as 60 to 80 bpm during surgery, expressed as percent of case minutes. Vital signs are measured from start of surgery to end of surgery at 5 minute intervals or less. (NCT01208402)
Timeframe: Start of surgery to end of surgery, an average duration of 245 minutes

Interventionpercentage of case minutes (Median)
Long-Acting Beta Blocker39.2
Esmolol37.3

[back to top]

Percentage of Intraoperative Case Time With Systolic Blood Pressure <95 mmHg

Duration of intraoperative case time patient was not in the target window of SBP > 95 mmHg, expressed as percent of total case minutes. SBP is measured from start of surgery to end of surgery at 5 minute intervals or less. (NCT01208402)
Timeframe: Start of surgery to end of surgery, an average duration of 245 minutes

Interventionpercentage of surgery minutes (Median)
Long-Acting Beta Blocker3.3
Esmolol3.1

[back to top]

Percentage of Postoperative First Three Hours With Heart Rate (HR) <60 or >80 Bpm

Duration of postoperative first three hours spent outside Target HR range defined as 60 to 80 bpm, expressed as percent of the total 3 hours. Vital signs are measured from end of surgery to 3 hours postoperatively at 5 minute intervals for the first hour and every 15 minutes thereafter. (NCT01208402)
Timeframe: End of surgery to 3 hours

Interventionpercentage of 3 hour interval (Median)
Long-Acting Beta Blocker56.5
Esmolol39.2

[back to top]

Percentage of Postoperative First Three Hours With Systolic Blood Pressure <95 mmHg

Duration of postoperative first three hours patient was not in the target window of SBP > 95 mmHg, expressed as percent of the total 3 hours. SBP is measured from end of surgery to 3 hours postoperatively at 5 minute intervals for first hour and every 15 minutes thereafter. (NCT01208402)
Timeframe: end of surgery to 3 hours

Interventionpercentage of 3 hour interval (Median)
Long-Acting Beta Blocker0
Esmolol0

[back to top]

Percentage of Postoperative Hours 4 to 12 With Heart Rate (HR) <60 or >80 Bpm.

Duration of postoperative hours 4 to 12 spent outside Target HR range defined as 60 to 80 bpm, expressed as percent of the total 9 hours. Vital signs are measured during hours four and five at 30 minute intervals and once every hour for the next 7 hours, through 12 hours postoperatively. (NCT01208402)
Timeframe: Postoperative hours 4-12

Interventionpercentage of 8 hour interval (Median)
Long-Acting Beta Blocker39.5
Esmolol37

[back to top]

Percentage of Postoperative Hours 4 to 12 With Systolic Blood Pressure <95 mmHg

Duration of postoperative hours 4 to 12 patient was not in the target window of SBP > 95 mmHg, expressed as percent of the total 9 hours. SBP was measured during hours four and five at 30 minute intervals and once every hour for the next 7 hours, through 12 hours postoperatively. (NCT01208402)
Timeframe: Postoperative hours 4-12

Interventionpercentage of 8 hour interval (Median)
Long-Acting Beta Blocker0
Esmolol6.8

[back to top]

Diastolic Blood Pressure Excursions Beyond Predetermined Lower Limits, Normalized Per Hour

Area under the curve (AUC) of Diastolic Blood Pressure Excursions Beyond Predetermined Lower Limits, Normalized Per Hour from Anesthesia Induction to Initiation of Cardiopulmonary Bypass (NCT01212874)
Timeframe: Participants were followed from Anesthesia Induction to Initiation of Cardiopulmonary Bypass, an average of 5 hours

InterventionmmHg*min/prebypass hour (Median)
Esmolol97.9
Nitroglycerin45.6

[back to top]

Title: Systolic Hypertension

Area under the curve (AUC) of Systolic Blood Pressure Excursions Beyond Predetermined Upper Limits, Normalized Per Hour from Anesthesia Induction to Initiation of Cardiopulmonary Bypass (NCT01212874)
Timeframe: Participants were followed from Anesthesia Induction to Initiation of Cardiopulmonary Bypass, an average of 5 hours

InterventionmmHg*min / prebypass hour (Median)
Esmolol48.6
Nitroglycerin145.8

[back to top]

Post Operative Pain Reported by the Subject.

Post operative pain reported by the subject as determined as area under the numeric rating scale for pain versus time curve in the post anesthesia care unit ( score*min).Numeric rating scale for pain on a scale of 0-10 (0 is no pain and 10 is high pain) versus time curve in the post anesthesia care unit ( score * min). A higher value indicates more pain over 24 hours.The range is 0 pain to x time in minutes x hour ( 60-1440 minutes) . The pain scores were collected at 15 minute intervals from the time of admission to the PACU to 24 hours after the surgical procedure. The area under the NRS pain scale versus time curve was calculated using the trapezoidal method as an indicator of pain burden during early recovery (Graph Pad Prism ver 5.03, Graph Pad Software INC. (NCT01782898)
Timeframe: 24 hour

Intervention(pain score * minutes ) in the PAC U (Median)
Esmolol218
.9 Normal Saline150

[back to top]

Postoperative Opioid Consumption

The total amount of opioid consumed by subject at 24 hours after surgery measured in IV morphine equivalents. (NCT01782898)
Timeframe: 24 hours

InterventionIV mg of morpine equivalents (Median)
Esmolol2.5
.9 Normal Saline0

[back to top]

Qor-40 at 24 Hours Postoperative

"Quality of recovery questionnaire score at 24 hours after surgery. Quality of recovery score 24 hours after the surgical procedure.Score of 40 is poor recovery and a score of 200 is good recovery.~Time frame for this evaluation is 24 hours after the surgical procedure" (NCT01782898)
Timeframe: 24 hours

Interventionunits on a scale 40 low-200 high (Median)
Esmolol179
.9 Normal Saline182

[back to top]

Failure of Drug to Control Systolic Blood Pressure (SBP) < 140 mmHg

(NCT01951950)
Timeframe: 1 hour postoperatively

Interventionparticipants (Number)
Nicardipine1
Esmolol11

[back to top]

Lactate

Median percent change from baseline lactate measured at the 6, 12, and 24 hour time points after study initiation between groups. Percent change was calculated by subtracting the later lactate from the baseline lactate and dividing the difference by the baseline lactate (i.e. (baseline lactate - 6h lactate)/baseline lactate). (NCT02369900)
Timeframe: 6, 12, and 24 hours

,
Interventionpercent change from baseline (Median)
6 hours12 hours24 hours
Esmolol Infusion16.727.530.4
Standard Care, Saline08.819.1

[back to top]

Overall Need for Vasopressor Support

While the primary endpoint will be mean norepinephrine dose at 6h, we will also measure mean vasopressor dose in groups at 12h and 24h. (NCT02369900)
Timeframe: 12 and 24 hours

,
Interventionmcg/kg/min (Mean)
12 hours24 hours
Esmolol Infusion0.310.24
Standard Care, Saline0.170.16

[back to top]

Oxygen Consumption (VO2)

To analyze the difference in oxygen consumption between groups at 12 hours, 24 hours and over time for patients who were on mechanical ventilation at enrollment, VO2 measurements were compared (standardized by bodyweight in kilograms) over time (recorded every minute from the time of study drug administration over a period of at least 24 hours) between groups using mixed linear model accounting for repeated measures. Using an unadjusted model, mean differences at 12 hours, 24 hours and for differences in the overall trend over time were tested. (NCT02369900)
Timeframe: 12 and 24 hours

,
InterventionmL/kg/min (Median)
12 hours24 hours
Esmolol Infusion3.784.13
Standard Care, Saline4.294.83

[back to top]

TNF-alpha

To characterize effects of esmolol on inflammatory markers in patients with vasopressor-dependent septic shock, we compared log-transformed values of TNF-alpha at 12 and 24 hours and over time between groups using mixed linear model accounting for repeated measures and adjusting for pre-intervention levels. (NCT02369900)
Timeframe: 12 and 24 hours

,
Interventionpg/mL (Median)
12 hours24 hours
Esmolol Infusion4.54.4
Standard Care, Saline8.77.5

[back to top]

Heart Rates Between Groups

We will measure median heart rate at the 6 and 12h time points. (NCT02369900)
Timeframe: 6 and 12 hours

,
Interventionbeats per minutes (Median)
6 hours12 hours
Esmolol Infusion9289
Standard Care, Saline9896

[back to top]

C-reactive Protein

To characterize effects of esmolol on inflammatory markers in patients with vasopressor-dependent septic shock, we compared log-transformed values of C-reactive protein at 12 and 24 hours and over time between groups using mixed linear model accounting for repeated measures and adjusting for pre-intervention levels. (NCT02369900)
Timeframe: 12 and 24 hours

,
Interventionpg/mL (Median)
12 hours24 hours
Esmolol Infusion140.5155.2
Standard Care, Saline170.2189.7

[back to top]

Interleukin-10

To characterize effects of esmolol on inflammatory markers in patients with vasopressor-dependent septic shock, we compared log-transformed values of interleukin-10 at 12 and 24 hours and over time between groups using mixed linear model accounting for repeated measures and adjusting for pre-intervention levels. (NCT02369900)
Timeframe: 12 and 24 hours

,
Interventionpg/mL (Median)
12 hours24 hours
Esmolol Infusion3.53.4
Standard Care, Saline5.42.8

[back to top]

Time to Shock Reversal

Time to shock reversal (cessation of all vasopressors for at least 12h). (NCT02369900)
Timeframe: Duration of hospitalization, limit 180 days

Interventiondays (Median)
Esmolol Infusion3.9
Standard Care, Saline2.5

[back to top]

Need for Vasopressor Support, Measured as Mean Norepinephrine Equivalent Dose (mcg/kg/Min), at 6hr Time Point

The primary endpoint will be mean norepinephrine equivalent dose (mcg/kg/min) at 6 hours after onset of study drug. For the vasopressor vasopressin, the dose of vasopressin was multiplied by 2.5 in order to create a norepinephrine equivalent dose. For the vasopressor phenylephrine, the dose of phenylephrine was divided by 10 in order to create a norepinephrine equivalent dose. (NCT02369900)
Timeframe: 6 hours

Interventionmcg/kg/min (Mean)
Esmolol Infusion0.30
Standard Care, Saline0.21

[back to top]

Interleukin-4

To characterize effects of esmolol on inflammatory markers in patients with vasopressor-dependent septic shock, we compared log-transformed values of interleukin-4 at 12 and 24 hours and over time between groups using mixed linear model accounting for repeated measures and adjusting for pre-intervention levels. (NCT02369900)
Timeframe: 12 and 24 hours

,
Interventionpg/mL (Median)
12 hours24 hours
Esmolol Infusion0.0270.016
Standard Care, Saline0.0230.018

[back to top]

Interleukin-6

To characterize effects of esmolol on inflammatory markers in patients with vasopressor-dependent septic shock, we compared log-transformed values of interleukin-6 at 12 and 24 hours and over time between groups using mixed linear model accounting for repeated measures and adjusting for pre-intervention levels. (NCT02369900)
Timeframe: 12 and 24 hours

,
Interventionpg/mL (Median)
12 hours24 hours
Esmolol Infusion62.354.4
Standard Care, Saline78.339.0

[back to top]

All-cause Mortality

(NCT02841241)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
Esmolol0

[back to top]

Development of Heart Block

(NCT02841241)
Timeframe: for duration of esmolol infusion, an expected average of 2 days

InterventionParticipants (Count of Participants)
Esmolol0

[back to top]

Left Ventricular Global Longitudinal Strain at 24 Hours

(NCT02841241)
Timeframe: Day 1

InterventionPercentage of myocardial shortening (%) (Median)
Esmolol-15.8

[back to top]

Number of Participants With Intolerance to Esmolol Infusion at Any Given Rate

"Patients who met a prespecified stop event for esmolol titration, suggesting intolerance to a given infusion rate.~Per protocol, study drug titration: The target heart rate is 85 bpm. Start study drug infusion at 20 mcg/kg/min, without bolus, if HR (heart rate) ≥ 100 bpm. If HR >90 bpm and <100 bpm, start study drug infusion at 10 mcg/kg/min, without bolus. Increase by 20 mcg/kg/min every 20 minutes as long as HR > 90 bpm, to a maximum dose of 100 mcg/kg/min. If HR < 80 bpm and > 70 bpm, decrease infusion rate by 10 mcg/kg/min; if HR ≤ 70 bpm and > 60 bpm, decrease infusion rate by 20 mcg/kg/min." (NCT02841241)
Timeframe: duration of esmolol infusion (~2 days)

InterventionParticipants (Count of Participants)
Esmolol3

[back to top]

Organ-failure-free Days

"As of day 28, the number of calendar days on which the patient receives none of (a) vasopressor therapy, (b) mechanical ventilation, or (c) renal replacement therapy. If the patients dies on or before day 28, they have -1 organ-failure-free days.~The resulting point-based score combines the probability of death and the number of days without organ failure.~Score of -1 = Death before day 28 (Lowest Score). Score of 28 = Patient has been successful at going 28 without any vasopressor therapy/mechanical ventilation/renal replacement therapy (Highest Score)" (NCT02841241)
Timeframe: Day 28

Interventionunits on a scale (Median)
Esmolol26

[back to top]

Peak Serum High-sensitivity Troponin

Measured after enrollment. (NCT02841241)
Timeframe: Troponin is measured on day 0 and day 1 (first day of esmolol infusion is day 0)

Interventionng/ml (Median)
Esmolol0.14

[back to top]

Percentage Hourly Checks During Which Protocol Compliance Was Observed

"For the esmolol titration protocol, each hour (the closest value of heart rate to the hour) during the esmolol infusion will be determined to be in range or out of range, with 3bpm margin for compliance (i.e., heart rate 77 to 93bpm). The initiation and cessation of esmolol will also be included as a timepoint for evaluation of compliance. Protocol compliance is considered adequate where overall compliance on hourly checks is >80%." (NCT02841241)
Timeframe: for duration of esmolol infusion, an expected average of 2 days

InterventionPercentage of hourly checks (Mean)
Esmolol98

[back to top]

Proportion of Compliance With Final Safety Check

(NCT02841241)
Timeframe: Day 0

InterventionParticipants (Count of Participants)
Esmolol7

[back to top]

Average Heart Rate

units of beats per minute, measured throughout the operation (NCT03661346)
Timeframe: Duration of operation up to 3 hours/completion of surgery

Interventionbpm (Mean)
Esmolol72
Labetalol69

[back to top]

Average Mean Arterial Blood Pressure

units of mmHg, measured throughout operation (NCT03661346)
Timeframe: Duration of operation up 3 hours/completion of operation

InterventionmmHg (Mean)
Esmolol79.7
Labetalol79.4

[back to top]

Intra-operative Surgical Visibility - Boezaart Scale

"Standardized scoring systems used by surgeons to rate surgical field quality in FESS:~Boezaart scale (0-5):~0 = no bleeding (optimal)~= slight bleeding with no suction required~= slight bleeding with occasional suctioning required~= slight bleeding with frequent suctioning required~= moderate bleeding with frequent suctioning required and surgical field visibility is compromised when suctioning is removed~= severe bleeding (worst) with constant suctioning required and compromised view" (NCT03661346)
Timeframe: Duration of operation

Interventionscore on a scale (Mean)
Esmolol3.1
Labetalol3.1

[back to top]

Intra-operative Surgical Visibility - Wormald Scale

"Standardized scoring systems used by surgeons to rate surgical field quality in FESS:~Wormald scale (0-10):~0 = No bleeding (optimal)~= 1-2 points of blood ooze~= 3-4 points of ooze~= 5-6 points of ooze~= 7-8 points of ooze~= 9-10 points of ooze~= >10 points of ooze, obscuring field~= Mild field bleeding with slow post-nasal accumulation~= Moderate field bleeding with moderate post-nasal accumulation~= Moderate-severe field bleeding with rapid post-nasal accumulation~= Severe bleeding (worst) with nose filling rapidly" (NCT03661346)
Timeframe: Duration of operation up to 3 hours

Interventionscore on a scale (Mean)
Esmolol6.1
Labetalol5.9

[back to top]

Rate of Blood Loss

milliliters per minute (NCT03661346)
Timeframe: Duration of operation up to 3 hours

InterventionmL/min (Mean)
Esmolol.59
Labetalol.66

[back to top]

Proportion of Subjects Achieving Target Ulcer Closure Within 12-week Treatment Phase, as Assessed by Blinded Investigator

Proportion of complete closure of wounds within 12-week treatment phase where Complete wound closure is defined as complete skin re-epithelialization that is without drainage or dressing requirements evaluated in two visits two weeks apart from first observation of closure. (NCT03998436)
Timeframe: Wound closure assessed up to week 12 and confirmed by 2 visits 2 weeks apart; only participants with wound closure at or before Week 12 and who maintained closure after 4-weeks of follow-up reported

InterventionParticipants (Count of Participants)
Galnobax® 14% Gel Plus SoC41
SoC Only30
Vehicle Plus SoC10

[back to top]

Proportion of Subjects With Treatment Emergent Adverse Events (TEAEs)

Proportion of Treatment emergent adverse events (TEAEs) in all the groups (NCT03998436)
Timeframe: 24-weeks

InterventionParticipants (Count of Participants)
Galnobax® 14% Gel Plus SoC10
SoC Only14
Vehicle Plus SoC9

[back to top]

Proportion of Subjects Achieving Target Ulcer Closure Till End of Study, as Assessed by the Blinded Investigator.

Proportion of complete closure of wounds at 24-weeks or End of Study where Complete wound closure is defined as complete skin re-epithelialization that is without drainage or dressing requirements. (NCT03998436)
Timeframe: 24-weeks. The ulcers achieving complete closure till end of study

InterventionParticipants (Count of Participants)
Galnobax® 14% Gel Plus SoC44
SoC Only35
Vehicle Plus SoC9

[back to top]